var title_f24_34_25120="Amalgam tattoo";
var content_f24_34_25120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amalgam tattoo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This area of blue-black pigment in the oral cavity is consistent with an amalgam tattoo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25120=[""].join("\n");
var outline_f24_34_25120=null;
var title_f24_34_25121="Klippel-Trenaunay syndrome - leg";
var content_f24_34_25121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Klippel-Trenaunay syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A capillary malformation and limb hypertrophy are present on the right leg of this child with Klippel-Trenaunay syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25121=[""].join("\n");
var outline_f24_34_25121=null;
var title_f24_34_25122="Patient information: Liver transplant (The Basics)";
var content_f24_34_25122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/42/44706\">",
"         Patient information: Liver cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/34/2594\">",
"         Patient information: Primary biliary cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/45/31447\">",
"         Patient information: Hepatitis B (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/4/17478\">",
"         Patient information: Hepatitis C (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Liver transplant (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H94655137\">",
"      <span class=\"h1\">",
"       What is a liver transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A liver transplant is a type of surgery in which a doctor replaces your diseased liver with a healthy liver.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94655152\">",
"      <span class=\"h1\">",
"       Why might I need a liver transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might need a liver transplant if you have severe liver disease. This is a condition in which the liver does not work the way it should. It can cause symptoms such as tiredness and swelling in the legs and belly. It can also make the skin or whites of the eyes look yellow. This is called &ldquo;jaundice.&rdquo;",
"     </p>",
"     <p>",
"      Before you have a liver transplant, your doctor will try other treatments. Your doctor will only recommend a liver transplant if no other treatments work.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94655169\">",
"      <span class=\"h1\">",
"       What happens before I can get a liver transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you get a liver transplant, you need to go through several steps.",
"     </p>",
"     <p>",
"      Your doctor will send you to a liver transplant center (a hospital that does liver transplants). If you are very sick, you might stay in the hospital. You will have exams and blood tests and talk with different doctors. Doctors will ask about your:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Other medical conditions and medicines you take",
"       </li>",
"       <li>",
"        Lifestyle (for example, alcohol, drug use, or smoking)",
"       </li>",
"       <li>",
"        Family and other support systems",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Not everyone who goes to a liver transplant center gets a transplant. To be considered, you must meet certain conditions. For example, you must:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe liver disease that has not gotten better with other treatments",
"       </li>",
"       <li>",
"        Not have serious heart and lung disease, such as COPD",
"       </li>",
"       <li>",
"        Not have cancer now or in the last 5 years",
"       </li>",
"       <li>",
"        Not use alcohol or drugs",
"       </li>",
"       <li>",
"        Be willing to take medicines for the rest of your life after surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you meet all these conditions, you will be put on a waiting list for a new liver. An organization called &ldquo;UNOS&rdquo; keeps track of everyone on the list. UNOS tries to give livers to the sickest people first. Your doctors will let UNOS know if your liver disease gets worse.",
"     </p>",
"     <p>",
"      A few people get a liver transplant from a friend or family member who gives part of his or her liver. For example, a parent might give part of a liver to a child. But most people get a new liver from UNOS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94655186\">",
"      <span class=\"h1\">",
"       What happens when a liver becomes available?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When a liver becomes available, UNOS chooses the person who is the best match for it. People who are waiting for a liver need to carry a cell phone or pager at all times so that they can be reached quickly.",
"     </p>",
"     <p>",
"      When you get called for your liver transplant, you will need to get to the hospital quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94655203\">",
"      <span class=\"h1\">",
"       What happens after a liver transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, most people stay in the hospital for a few weeks before going home. Your doctors will do tests regularly to make sure that your new liver is working correctly.",
"     </p>",
"     <p>",
"      After a liver transplant, people need to take medicines for the rest of their life. These medicines are called &ldquo;anti-rejection medicines.&rdquo; They help the body&rsquo;s infection-fighting system accept the new liver. Normally, the infection-fighting system helps people stay healthy by attacking objects in the body that came in from the outside (&ldquo;foreign objects&rdquo;). Anti-rejection medicines help keep the body from attacking the new liver.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94655218\">",
"      <span class=\"h1\">",
"       What problems can people have after a liver transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people do well after surgery. They can go to work and be active. But other people have problems right after the surgery or a few years later. These problems can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rejection of the new liver &ndash; Even though people take anti-rejection medicines, their body might still reject and attack the new liver.",
"       </li>",
"       <li>",
"        Liver disease that comes back &ndash; Some liver diseases can come back after a transplant, though not all do.",
"       </li>",
"       <li>",
"        Side effects from the anti-rejection medicines &ndash; These medicines have short-term side effects. For example, they increase a person&rsquo;s chance of getting infections. They also have long-term side effects. For example, they can increase the chance of certain types of cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94655233\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=see_link\">",
"       Patient information: Liver cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/34/2594?source=see_link\">",
"       Patient information: Primary biliary cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       Patient information: Hepatitis B (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       Patient information: Hepatitis C (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/34/25122?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86455 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25122=[""].join("\n");
var outline_f24_34_25122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655137\">",
"      What is a liver transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655152\">",
"      Why might I need a liver transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655169\">",
"      What happens before I can get a liver transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655186\">",
"      What happens when a liver becomes available?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655203\">",
"      What happens after a liver transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655218\">",
"      What problems can people have after a liver transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94655233\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/34/2594?source=related_link\">",
"      Patient information: Primary biliary cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25123="Patient information: Colon and rectal cancer screening (The Basics)";
var content_f24_34_25123=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16186\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/52/19265\">",
"           Colonoscopy versus sigmoidoscopy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/27/19890\">",
"         Patient information: Colon and rectal cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9298\">",
"         Patient information: Colon polyps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/0/6148\">",
"         Patient information: Colon and rectal cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7541\">",
"         Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/9/25747\">",
"         Patient information: Colon polyps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/30/9698\">",
"         Patient information: Colonoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/40/24196\">",
"         Patient information: Crohn's disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/12/42176\">",
"         Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Colon and rectal cancer screening (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/colon-and-rectal-cancer-screening-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19886353\">",
"      <span class=\"h1\">",
"       What is colon and rectal cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Colon and rectal cancer screening is a way in which doctors check the colon and rectum for signs of cancer or growths (called polyps) that might become cancer. It is done in people who have no symptoms and no reason to think they have cancer. The goal is to find and remove polyps before they become cancer, or to find cancer early, before it grows, spreads, or causes problems.",
"     </p>",
"     <p>",
"      The colon and rectum are the last part of the digestive tract (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). When doctors talk about colon and rectal cancer screening, they use the term &ldquo;colorectal.&rdquo; That is just a shorter way of saying &ldquo;colon and rectal.&rdquo; It&rsquo;s also possible to say just colon cancer screening.",
"     </p>",
"     <p>",
"      Studies show that having colon cancer screening lowers the chance of dying from colon cancer. There are 4 or 5 screening tests that can do this. They will be described here.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19886360\">",
"      <span class=\"h1\">",
"       What are the different screening tests for colon cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Colonoscopy",
"        </strong>",
"        &ndash; Colonoscopy allows the doctor to see directly inside the entire colon. Before you can have a colonoscopy, you must clean out your colon. You do this by drinking a special liquid that causes watery diarrhea. On the day of the test, you get medicine to help you relax. Then a doctor puts a thin tube into your anus and advances it into your colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ). The tube has a camera attached to it, so the doctor can see inside your colon. The tube also has tools on the end, so the doctor can remove pieces of tissue, or polyps if they are there. After polyps or pieces of tissue are removed, they are sent to a lab to be checked for cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Advantages of this test &ndash; Colonoscopy finds most small polyps and almost all large polyps and cancers. If found, polyps can be removed right away.",
"       </li>",
"       <li>",
"        Drawbacks to this test &ndash; Colonoscopy has more risks than the other screening tests. In 1 in 1,000 people, it can cause bleeding or tear the inside of the colon. Cleaning out the bowel beforehand can be unpleasant. Plus, people usually cannot work or even drive themselves home the day of the test, because of the relaxation medicine they must take during the test.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Sigmoidoscopy",
"        </strong>",
"        &ndash; A sigmoidoscopy is very similar to a colonoscopy. The difference is that this test looks only at the last part of the colon, and a colonoscopy looks at the whole colon. Before you have a sigmoidoscopy, you must clean out the lower part of your colon using an enema. This bowel cleaning is not as thorough or unpleasant as the one for colonoscopy. For this test, you do not need to take medicines to help you relax, so you can drive and work afterward if you want.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Advantages of this test &ndash; Sigmoidoscopy can find polyps and cancers in the rectum and the last part of the colon. If polyps are found, they can be removed right away.",
"       </li>",
"       <li>",
"        Drawbacks to this test &ndash; In about 2 out of 10,000 people, sigmoidoscopy tears the inside of the colon. The test also can&rsquo;t find polyps or cancers that are in the part of the colon the test does not view (",
"        <a class=\"graphic graphic_figure graphicRef58734 \" href=\"UTD.htm?18/52/19265\">",
"         figure 3",
"        </a>",
"        ). If doctors find polyps or cancer during a sigmoidoscopy, they usually follow up with a colonoscopy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         CT colonography",
"        </strong>",
"        (also known as virtual colonoscopy or CTC) &ndash; CTC looks for cancer and polyps using a special X-ray called a &ldquo;CT scan.&rdquo; For most CTC tests, the preparation is the same as it is for colonoscopy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Advantages of this test &ndash; CTC can find polyps and cancers in the whole colon without the need for medicines to relax.",
"       </li>",
"       <li>",
"        Drawbacks to this test &ndash; If doctors find polyps or cancer with CTC, they usually follow up with a colonoscopy. CTC sometimes finds areas that look abnormal but that turn out to be healthy. This means that CTC can lead to tests and procedures you did not need. Plus, CTC exposes you to radiation. In most cases, the preparation needed to clean the bowel is the same as the one needed for a colonoscopy. The test is expensive, and many insurance companies do not cover this test for screening.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Stool test for blood &ndash;",
"        </strong>",
"        &ldquo;Stool&rdquo; is another word for bowel movements. Stool tests most commonly check for blood in samples of stool. Cancers and polyps can bleed, so blood will show up in the stool. Other less serious conditions can also cause small amounts of blood in the stool, and that will show up in this test. You will have to collect small samples from bowel movements, which you will put on a special card and mail to your doctor or to a lab.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Advantages of this test &ndash; This test does not involve cleaning out the colon or having any procedures.",
"       </li>",
"       <li>",
"        Drawbacks to this test &ndash; Stool tests are less likely to find polyps than other screening tests. These tests also often come up abnormal even in people who do not have cancer. If a stool test shows something abnormal, doctors usually follow up with a colonoscopy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19886367\">",
"      <span class=\"h1\">",
"       How do I choose which test to have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Work with your doctor or nurse to decide which test is best for you. Being screened&mdash;no matter how&mdash;is more important than which test you choose.",
"     </p>",
"     <p>",
"      Some doctors prefer tests that can find polyps that could turn into cancer. These include colonoscopy, CT colonography, and sigmoidoscopy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19886374\">",
"      <span class=\"h1\">",
"       Who should be screened for colon cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend that most people begin having colon cancer screening at age 50. People who have an increased risk of getting colon cancer sometimes begin screening at a younger age. That might include people with a strong family history of colon cancer, and people with diseases of the colon called &ldquo;Crohn&rsquo;s disease&rdquo; and &ldquo;ulcerative colitis.&rdquo;",
"     </p>",
"     <p>",
"      Most people can stop being screened around the age of 75, or at the latest 85.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19886381\">",
"      <span class=\"h1\">",
"       How often should I be screened?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on your risk of colon cancer and which test you have.",
"     </p>",
"     <p>",
"      Most people can choose 1 of these schedules:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Colonoscopy every 10 years",
"       </li>",
"       <li>",
"        Computed tomography (CTC) every 5 years",
"       </li>",
"       <li>",
"        Sigmoidoscopy every 5 years",
"       </li>",
"       <li>",
"        Stool testing for blood once a year",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have a high risk of colon cancer often need to be tested more often and should have a colonoscopy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19886463\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       Patient information: Colon and rectal cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=see_link\">",
"       Patient information: Colon polyps (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       Patient information: Colon and rectal cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"       Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       Patient information: Colonoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=see_link\">",
"       Patient information: Colon polyps (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       Patient information: Crohn's disease (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/34/25123?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16186 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25123=[""].join("\n");
var outline_f24_34_25123=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19886353\">",
"      What is colon and rectal cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19886360\">",
"      What are the different screening tests for colon cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19886367\">",
"      How do I choose which test to have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19886374\">",
"      Who should be screened for colon cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19886381\">",
"      How often should I be screened?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19886463\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16186\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/52/19265\">",
"        Colonoscopy versus sigmoidoscopy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/9/25747?source=related_link\">",
"      Patient information: Colon polyps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9298?source=related_link\">",
"      Patient information: Colon polyps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25124="Ursodiol: Patient drug information";
var content_f24_34_25124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ursodiol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     see \"Ursodiol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"     see \"Ursodiol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actigall&reg;;",
"     </li>",
"     <li>",
"      Urso 250&reg;;",
"     </li>",
"     <li>",
"      Urso Forte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Ursodiol C;",
"     </li>",
"     <li>",
"      PHL-Ursodiol C;",
"     </li>",
"     <li>",
"      PMS-Ursodiol C;",
"     </li>",
"     <li>",
"      Urso&reg;;",
"     </li>",
"     <li>",
"      Urso&reg; DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat gallstones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ursodiol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bile acids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697183",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have biliary tract problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules and tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11900 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-49496BE7AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25124=[""].join("\n");
var outline_f24_34_25124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232635\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232636\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028719\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028718\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028723\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028724\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028726\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028721\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028722\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028727\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028728\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=related_link\">",
"      Ursodiol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=related_link\">",
"      Ursodiol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25125="Typhoid vaccine: Pediatric drug information";
var content_f24_34_25125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Typhoid vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"    see \"Typhoid vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/59/10161?source=see_link\">",
"    see \"Typhoid vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Typhim Vi&reg;;",
"     </li>",
"     <li>",
"      Vivotif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5275259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Typherix&reg;;",
"     </li>",
"     <li>",
"      Typhim Vi&reg;;",
"     </li>",
"     <li>",
"      Vivotif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1041432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1041450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"      see \"Typhoid vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (Vivotif&reg;): Children &ge;6 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary immunization: One capsule on alternate days (day 1, 3, 5, and 7) for a total of 4 doses; all doses should be completed at least 1 week prior to potential exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reimmunization: Repeat full course of primary immunization every 5 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. (Typhim Vi&reg;): Children &ge;2 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary immunization: 0.5 mL given at least 2 weeks prior to expected exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reimmunization: 0.5 mL; optimal schedule has not been established; a single dose every 2 years is currently recommended for repeated or continued exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     There is no data concerning using one vaccine (oral vs. I.M.) as a booster after primary immunization with the other vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, enteric coated [live]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivotif&reg;: Viable",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty21a 2-6.8 x 10",
"     <sup>",
"      9",
"     </sup>",
"     colony-forming units and nonviable",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty21a 5-50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     bacterial cells [contains lactose 100-180 mg/capsule and sucrose 26-130 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [inactivated]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Typhim Vi&reg;: Purified Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL, 10 mL) [derived from",
"     <i>",
"      S. typhi",
"     </i>",
"     Ty2 strain]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1041454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer by I.M. injection into the anterolateral aspect of the thigh or arm;",
"     <b>",
"      not for I.V. or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Oral capsule should be taken 1 hour before a meal with cold or lukewarm drink on alternate days (days 1, 3, 5, and 7); swallow capsule whole, do not chew",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1041444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refrigerate at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1041433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization to prevent disease from exposure to",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     ; use is not routinely recommended in the U.S. but is reserved for selected individuals who are either traveling to an area in which there is a recognized risk of exposure to",
"     <i>",
"      S. typhi",
"     </i>",
"     , who have intimate exposure (eg, household contact) to a",
"     <i>",
"      S. typhi",
"     </i>",
"     carrier, or who work frequently with",
"     <i>",
"      S. typhi",
"     </i>",
"     in laboratory settings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Typhim Vi&reg;: Approved for use in children &ge;2 years and adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Live attenuated Ty21a vaccine (Vivotif&reg;): Approved for use in children &ge;6 years and adults",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F232383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      In the U.S., all serious adverse reactions must be reported to the Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Induration, pain, soreness, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever &ge;100&deg;F",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Erythema, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, allergic reactions, anaphylaxis, arthralgia, cervical pain, diarrhea, dizziness, flu-like syndrome, Guillain-Barr&eacute; syndrome, hypotension, injection site inflammation (including angioedema and urticaria), loss of consciousness, lymphadenopathy, malaise, perforated jejunum, rash, serum sickness, tremor, urticaria, vasodilation, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic reaction, demyelinating disease, myalgia, pain, RA, urticaria, sepsis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1041435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to the vaccine or any component; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; concurrent immunosuppressive therapy; primary and acquired immunodeficiency states; family history of congenital or hereditary immunodeficiency; current febrile illness or active febrile infection, oral formulation only: Acute GI illness, persistent diarrhea or vomiting, concurrent systemic antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3985926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vivotif&reg; should not be administered to immunocompromised persons, including those known to be infected with HIV. Parenteral inactivated vaccine may be an alternative for these individuals. Use with caution the parenteral inactivated vaccine (Typhim Vi&reg;) in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer Typhim Vi&reg; with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1041436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not all recipients of typhoid vaccine will be fully protected against typhoid fever; demonstrated efficacy ranges from 50% to 80%. Travelers should take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water sources. Unless a complete immunization schedule with oral live attenuated Ty21a vaccine (Vivotif&reg;) is followed, an optimum immune response may not be achieved. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antibiotics: May diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acetic Acid; Aluminum Acetate; Azithromycin (Ophthalmic); Bacitracin; Benzoin; Capreomycin; Ciprofloxacin (Ophthalmic); Clindamycin (Topical); Dapsone (Topical); Erythromycin (Ophthalmic); Erythromycin (Topical); Fidaxomicin; Gatifloxacin; Gentamicin (Ophthalmic); Gentamicin (Topical); Gentian Violet; Hexachlorophene; Mafenide; MetroNIDAZOLE (Topical); Neomycin; Oxychlorosene; Polymyxin B; Povidone-Iodine (Topical); Rifaximin; Silver Nitrate; Silver Sulfadiazine; Sulfacetamide (Ophthalmic); Sulfacetamide (Topical); Tobramycin (Ophthalmic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4039581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. The manufacturer of the Typhim Vi&reg; injection suggests delaying vaccination until the 2nd or 3rd trimester if possible. Untreated typhoid fever may lead to miscarriage or vertical intrauterine transmission causing neonatal typhoid (rare).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1041446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each vaccine formulation promotes immunity to disease caused by",
"     <i>",
"      Salmonella typhi.",
"     </i>",
"     I.M. formulation (Typhim Vi&reg;) is an inactivated vaccine which contains the cell surface Vi polysaccharide extracted from",
"     <i>",
"      Salmonella enterica serovar typhi",
"     </i>",
"     ,",
"     <i>",
"      S typhi",
"     </i>",
"     Ty2 strain. Oral formulation (Vivotif&reg;) is a live attenuated virus vaccine which confers immunity by provoking a local immune response in the intestinal tract.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1041447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immunity to",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     : Oral: ~1 week; I.M.: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immunity: Oral: ~5 years; Parenteral: ~3 years",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10285524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events.   If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25125/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25125/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Typhoid Immunization. Recommendations of the advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1994, 43(RR-14):1-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25125/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25125/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2006 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 27th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2006.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13020 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25125=[""].join("\n");
var outline_f24_34_25125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232369\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275259\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041432\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041450\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232355\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041454\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041444\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041433\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232383\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041435\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3985926\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041436\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300191\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232350\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232352\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039581\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929268\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041446\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1041447\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10285524\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13020|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=related_link\">",
"      Typhoid vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/59/10161?source=related_link\">",
"      Typhoid vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25126="Caffeine: Drug information";
var content_f24_34_25126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Caffeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42803?source=see_link\">",
"    see \"Caffeine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/20/32069?source=see_link\">",
"    see \"Caffeine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cafcit&reg;;",
"     </li>",
"     <li>",
"      Enerjets [OTC];",
"     </li>",
"     <li>",
"      No Doz&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Vivarin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant;",
"     </li>",
"     <li>",
"      Phosphodiesterase Enzyme Inhibitor, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Caffeine and sodium benzoate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Electroconvulsive therapy: I.V.: 300-2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory depression: I.M., I.V.: 250 mg as a single dose; may repeat as needed. Maximum single dose should be limited to 500 mg; maximum amount in any 24-hour period should generally be limited to 2500 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spinal puncture headache (unlabeled use):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: 500 mg in 1000 mL NS infused over 1 hour, followed by 1000 mL NS infused over 1 hour; a second course of caffeine can be given for unrelieved headache pain in 4 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 300 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stimulant/diuretic (unlabeled use): I.M., I.V.: 500 mg, maximum single dose: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OTC labeling (stimulant): Oral: 100-200 mg every 3-4 hours as needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/20/32069?source=see_link\">",
"      see \"Caffeine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Caffeine citrate should not be interchanged with the caffeine sodium benzoate formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Caffeine citrate:",
"     </b>",
"     Apnea of prematurity: Neonates: Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 10-20 mg/kg as caffeine citrate (5-10 mg/kg as caffeine base). If theophylline has been administered to the patient within the previous 3 days, a full or modified loading dose (50% to 75% of a loading dose) may be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 5 mg/kg/day as caffeine citrate (2.5 mg/kg/day as caffeine base) once daily starting 24 hours after the loading dose. Maintenance dose is adjusted based on patient's response and serum caffeine concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Caffeine and sodium benzoate:",
"     </b>",
"     Stimulant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V., SubQ: 8 mg/kg every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: OTC labeling: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F144015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NoDoz&reg; Maximum Strength, Vivarin&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as citrate [preservative free]: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cafcit&reg;: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [with sodium benzoate]: Caffeine 125 mg/mL and sodium benzoate 125 mg/mL (2 mL); caffeine 121 mg/mL and sodium benzoate 129 mg/mL (2 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enerjets&reg;: 75 mg (12s) [classic coffee, hazelnut cream, or mochamint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as citrate [preservative free]: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cafcit&reg;: 20 mg/mL (3 mL) [equivalent to 10 mg/mL caffeine base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivarin&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet, caffeine and sodium benzoate injection, injection, oral solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F143993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to feedings or meals. May administer injectable formulation (caffeine citrate) orally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Caffeine citrate:",
"     </b>",
"     Infuse loading dose over at least 30 minutes; maintenance dose may be infused over at least 10 minutes. May administer without dilution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Caffeine and sodium benzoate:",
"     </b>",
"     I.V. as slow direct injection. For spinal headaches, infuse diluted solution over 1 hour. Follow with 1000 mL NS; infuse over 1 hour. May administer I.M. undiluted.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeine citrate: Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      50",
"     </sub>",
"     W, Intralipid&reg; 20%, Aminosyn&reg; 8.5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alprostadil, amikacin, aminophylline, calcium gluconate, cefotaxime, cimetidine, clindamycin, dexamethasone, dobutamine, dopamine, doxapram, epinephrine, fentanyl, gentamicin, heparin, isoproterenol, levofloxacin, lidoacine, metoclopramide, morphine, nitroprusside, pancuronium, penicillin G potassium, phenobarbital, phenylephrine, sodium bicarbonate, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, furosemide, lorazepam, nitroglycerin, oxacillin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caffeine citrate: Treatment of idiopathic apnea of prematurity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caffeine and sodium benzoate: Treatment of acute respiratory depression (not a preferred agent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caffeine [OTC labeling]: Restore mental alertness or wakefulness when experiencing fatigue",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F144027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeine and sodium benzoate: Treatment of spinal puncture headache; CNS stimulant; diuretic; augmentation of seizure induction during electroconvulsive therapy (ECT)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not specified; primarily serum-concentration related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia (ventricular), chest pain, flushing, palpitation, sinus tachycardia, tachycardia (supraventricular), vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, delirium, dizziness, hallucinations, headache, insomnia, irritability, psychosis, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Esophageal sphincter tone decreased, gastritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fasciculations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased (&gt;180 mg caffeine), miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to caffeine or any component of the formulation; sodium benzoate is not for use in neonates",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anxiety: Avoid use in patients with anxiety, agitation, or tremor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; avoid use in patients with symptomatic cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with a history of peptic ulcer and/or gastroesophageal reflux.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Caffeine citrate should be closely monitored for the development of necrotizing enterocolitis in the neonate; caffeine serum levels should be closely monitored to optimize therapy and prevent serious toxicity. Avoid use of products containing sodium benzoate in neonates; has been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates, including metabolic acidosis, respiratory distress, gasping respirations, seizures, intracranial hemorrhage, hypotension, and cardiovascular collapse.",
"     <i>",
"      In vitro",
"     </i>",
"     and animal studies have shown that benzoate also displaces bilirubin from protein-binding sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC products: Over-the-counter [OTC] products contain an amount of caffeine similar to one cup of coffee; limit the use of other caffeine-containing beverages or foods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability:",
"     <b>",
"      Caffeine citrate should not be interchanged with caffeine and sodium benzoate.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F144025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F143998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeine crosses the placenta; serum levels in the fetus are similar to those in the mother. When large bolus doses are administered to animals, teratogenic effects have been reported. Similar doses are not probable following normal caffeine consumption and moderate consumption is not associated with congenital malformations, spontaneous abortions, preterm birth or low birth weight. According to one source, pregnant women who do not smoke or drink alcohol could consume &le;5 mg/kg of caffeine over the course of a day without reproductive risk. Other sources recommend limiting caffeine intake to &lt;150-200 mg/day. The half-life of caffeine is prolonged during the second and third trimesters of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F144019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F143999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeine is detected in breast milk; concentrations may be dependent upon maternal consumption and her ability to metabolize (eg, smoker versus nonsmoker). The ability of the breast-feeding child to metabolize caffeine is age dependant. Irritability and jitteriness have been reported in the nursing infant exposed to high concentrations of caffeine in breast milk. Infant heart rates and sleep patterns were not found to be affected in normal, full-term infants exposed to lesser amounts of caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9460174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral formulations may be taken without regard to feedings or meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cafcit Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/3 mL (3 mL): $49.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cafcit Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/3 mL (3 mL): $49.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Caffeine Citrate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/3 mL (3 mL): $42.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Caffeine Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/3 mL (3 mL): $42.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Caffeine-Sodium Benzoate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125-125 mg/mL (2 mL): $12.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Caffeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (16): $2.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (No Doz Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (36): $4.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vivarin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (16): $2.60",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F143991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: Apnea of prematurity: 8-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;50 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cafcit (GR);",
"     </li>",
"     <li>",
"      Cafnea (AU);",
"     </li>",
"     <li>",
"      Coffeinum Natrium Benzoicum (PL);",
"     </li>",
"     <li>",
"      Kofex (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases levels of 3'5' cyclic AMP by inhibiting phosphodiesterase; CNS stimulant which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction (diaphragmatic contractility); prevention of apnea may occur by competitive inhibition of adenosine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 0.8-0.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;9 months to Adults: 0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17% (children) to 36% (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via demethylation by CYP1A2.",
"     <b>",
"      Note:",
"     </b>",
"     In neonates, interconversion between caffeine and theophylline has been reported (caffeine levels are ~25% of measured theophylline after theophylline administration and ~3% to 8% of caffeine would be expected to be converted to theophylline)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 72-96 hours (range: 40-230 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;9 months and Adults: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Within 30 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates &le;1 month: 86% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;1 month and Adults: In urine, as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, \"ACOG Committee Opinion No. 462: Moderate Caffeine Consumption During Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 116(2 Pt 1):467-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/20664420/pubmed\" id=\"20664420\" target=\"_blank\">",
"        20664420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM Jr, \"Excretion of Methylxanthines in Human Milk,\"",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1981, 5(4):389-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/7302615/pubmed\" id=\"7302615\" target=\"_blank\">",
"        7302615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Choi A, Laurito CE, and Cunningham FE, &ldquo;Pharmacologic Management of Postdural Puncture Headache,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(7-8):831-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/8826568/pubmed\" id=\"8826568\" target=\"_blank\">",
"        8826568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Christian MS and Brent RL, &ldquo;Teratogen Update: Evaluation of the Reproductive and Developmental Risks of Caffeine,&rdquo;",
"      <i>",
"       Teratology",
"      </i>",
"      , 2001, 64(1):51-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/11410911/pubmed\" id=\"11410911\" target=\"_blank\">",
"        11410911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hildebrandt R and Gundert-Remy U, \"Lack of Pharmacological Active Saliva Levels of Caffeine in Breast-Fed Infants,\"",
"      <i>",
"       Pediatr Pharmacol",
"      </i>",
"      , 1983, 3(3-4):237-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/6677875/pubmed\" id=\"6677875\" target=\"_blank\">",
"        6677875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, &ldquo;Caffeine During Pregnancy? In Moderation,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2000, 46(4):801-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/10790810/pubmed\" id=\"10790810\" target=\"_blank\">",
"        10790810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mart&iacute;n I, L&oacute;pez-V&iacute;lchez MA, Mur A, et al, \"Neonatal Withdrawal Syndrome After Chronic Maternal Drinking of Mate,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2007, 29(1):127-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/17304161/pubmed\" id=\"17304161\" target=\"_blank\">",
"        17304161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryu JE, \"Caffeine in Human Milk and in Serum of Breast-Fed Infants,\"",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1985, 8(6):329-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/4075932/pubmed\" id=\"4075932\" target=\"_blank\">",
"        4075932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryu JE, \"Effect of Maternal Caffeine Consumption on Heart Rate and Sleep Time of Breast-Fed Infants,\"",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1985, 8(6):355-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/4075934/pubmed\" id=\"4075934\" target=\"_blank\">",
"        4075934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tyrala EE and Dodson WE, \"Caffeine Secretion Into Breast Milk,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1979, 54(10):787-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/507903/pubmed\" id=\"507903\" target=\"_blank\">",
"        507903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yucel A, Ozyalcin S, Talu GK, et al, &ldquo;Intravenous Administration of Caffeine Sodium Benzoate for Postdural Puncture Headache,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 1999, 24(1):51-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/34/25126/abstract-text/9952095/pubmed\" id=\"9952095\" target=\"_blank\">",
"        9952095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9213 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25126=[""].join("\n");
var outline_f24_34_25126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144010\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144030\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144013\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144024\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144014\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144015\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143990\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143978\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143993\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144036\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143992\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144027\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144028\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143996\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143981\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144025\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143985\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143987\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143998\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144019\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143999\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460174\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323030\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143991\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038545\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143980\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143995\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9213\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9213|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42803?source=related_link\">",
"      Caffeine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/20/32069?source=related_link\">",
"      Caffeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25127="Ess thrombocythemia marrow";
var content_f24_34_25127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow in essential thrombocythemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow biopsies from two different patients with essential thrombocythemia are shown here. Both patients met the Polycythemia Vera Study Group's criteria for this diagnosis. The most prominent finding in both cases is megakaryocytic hyperplasia, with clustering of megakaryocytes more prominent in the biopsy shown in the lower panel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Stephen A. Landaw, MD,PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25127=[""].join("\n");
var outline_f24_34_25127=null;
var title_f24_34_25128="Abdominal perineal resection (APR): Open technique";
var content_f24_34_25128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal perineal resection (APR): Open technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25128/contributors\">",
"     John RT Monson, MD, FRCS, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25128/contributors\">",
"     Fergal Fleming, MD, FRCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25128/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25128/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/34/25128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27174051\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal perineal resection (APR) includes the resection of the sigmoid colon, rectum, and anus (",
"    <a class=\"graphic graphic_figure graphicRef78498 \" href=\"UTD.htm?35/19/36148\">",
"     figure 1",
"    </a>",
"    ), and the construction of a permanent end colostomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174907\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign and malignant conditions that can be treated by APR include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crohn&rsquo;s proctitis with anal disease",
"     </li>",
"     <li>",
"      Ulcerative colitis, not a candidate or amenable to an ileal pouch anal anastomosis",
"     </li>",
"     <li>",
"      Fecal incontinence, not amenable to sphincter sparing procedures",
"     </li>",
"     <li>",
"      Low lying rectal cancer involving anal sphincter complex",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positive distal margin",
"     </li>",
"     <li>",
"      Anal cancer, failed neoadjuvant therapy",
"     </li>",
"     <li>",
"      Anal cancer, recurrent",
"     </li>",
"     <li>",
"      Anal melanoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174058\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174986\">",
"    <span class=\"h2\">",
"     Enterostomal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative counseling and education with a skilled enterostomal nurse therapist and site selection for optimal placement of the ostomy are the key components of preoperative preparation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link&amp;anchor=H21062994#H21062994\">",
"     \"Surgical principles of ostomy construction\", section on 'Preoperative preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174073\">",
"    <span class=\"h2\">",
"     Mechanical bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mechanical bowel preparation (MBP) is not included in preoperative preparation. A review of the evidence to omit a MBP is discussed separately. The use of mechanical bowel preparation (MBP) prior to colon and rectal surgery is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125365066#H125365066\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of data regarding MBP in patients with rectal cancer undergoing a low anterior resection. The benefit may depend upon the surgical procedure being performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subset analysis of a multicenter randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/1\">",
"       1",
"      </a>",
"      ] including 449 patients who had a low anterior resection (48 of 449 with a diverting colostomy) found no benefit for MBP [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/2\">",
"       2",
"      </a>",
"      ]. Compared with no MBP, patients undergoing a MBP had similar rates of leakage (about 7 percent), rate of complications, anastomotic dehiscence, intra-abdominal abscess, or mortality. &nbsp;",
"     </li>",
"     <li>",
"      However, in patients undergoing a sphincter saving resection for rectal cancer, MBP appears to be useful. A randomized trial of 178 patients undergoing a sphincter saving resection found lower overall morbidity and infection rates for patients undergoing a MBP compared with no MBP (27 versus 44 percent and 16 versus 34 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73475483\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our practice to give a first generation cephalosporin (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    intravenously within one hour of incision for an APR. We do not use oral antibiotics or continue prophylaxis postoperatively (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use and timing of antimicrobial prophylaxis for prevention of surgical site infection following gastrointestinal procedures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27175479\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing an APR are at a high risk for developing a deep venous thrombosis (DVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. All patients scheduled for an abdominoperineal resection should receive primary prophylaxis. Prevention of DVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174094\">",
"    <span class=\"h1\">",
"     OPEN SURGICAL TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174103\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to patient positioning is integral to preventing peripheral nerve injuries, pressure sores, deep vein thrombosis, and compartment syndrome (",
"    <a class=\"graphic graphic_figure graphicRef51144 \" href=\"UTD.htm?21/56/22403\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/6\">",
"     6",
"    </a>",
"    ]. To lower the risk of surface pressure and subsequent peripheral nerve injury, the authors place an inflated bean bag with a soft gel layer under the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/7\">",
"     7",
"    </a>",
"    ], which can be moulded around the patient when the air is evacuated. Operating room safety and a review of strategies to prevent nerve injury during pelvic surgery is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=see_link\">",
"     \"Operating room safety\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient is placed in the modified dorsal lithotomy position:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent pneumatic compression pumps are applied to both legs.",
"     </li>",
"     <li>",
"      The legs are raised simultaneously and secured in boots.",
"     </li>",
"     <li>",
"      The legs should be at the same height with the hips and knees flexed at 45 to 60&deg;.",
"     </li>",
"     <li>",
"      Adequate padding should be placed around the posterolateral aspect of lower legs to prevent a common peroneal nerve injury.",
"     </li>",
"     <li>",
"      The buttocks should be extended slightly over the end of the operating table so that the sacrum is supported on the bean bag surface, even with the lower break of the procedure bed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient&rsquo;s arms should either be padded and secured by the side of the patient, or secured on padded arm boards and extended no more than 90&ordm; [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/9\">",
"       9",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      For the severely obese patient, special operating tables with side extensions are used for added support [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/10\">",
"       10",
"      </a>",
"      ]. The shoulders should be padded to prevent pressure sores from the bean bag.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27175928\">",
"    <span class=\"h2\">",
"     Exploration for resectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating the resection, the abdomen is thoroughly examined for resectability of the sigmoid colon and rectum.",
"   </p>",
"   <p>",
"    For patients with cancer, this evaluation includes an assessment of local, regional, and distant disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The abdomen is explored for evidence of anomalies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic disease, including peritoneal implants, hepatic metastases, and distant nodal metastases.",
"     </li>",
"     <li>",
"      The primary tumor is palpated to confirm its location. Local and regional resectability is determined by assessing tumor invasion into the pelvic walls or organs (eg, prostate, bladder, and uterus). The entire colon is palpated to identify synchronous colonic lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27176001\">",
"    <span class=\"h2\">",
"     Mobilization of colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two approaches to mobilizing and resecting the sigmoid colon, medial to lateral (early ligation of vascular pedicle) or lateral to medial (early mobilization of the colon). The authors perform all dissections, both open and laparoscopic, in a medial to lateral fashion.",
"   </p>",
"   <p>",
"    The advantages of the early division of the vascular pedicle includes reduced bleeding during dissection, maximal time for sharp demarcation between ischemic and well-perfused bowel, and more efficient identification of the correct plane in the fine areolar tissue that connects the mesocolon to the mesentery. This approach helps to reduce the risk of injury to retroperitoneal structures such as the ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81824639\">",
"    <span class=\"h3\">",
"     Medial to lateral approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medial to lateral approach is ideal for resection of inflamed bowel and adjacent mesentery and for performing the &ldquo;no-touch&rdquo; approach to colon cancer resection (",
"    <a class=\"graphic graphic_figure graphicRef73756 \" href=\"UTD.htm?40/32/41479\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81960 \" href=\"UTD.htm?3/3/3127\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58219 \" href=\"UTD.htm?38/33/39448\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The general principles for performing a sigmoid colectomy, beginning with ligation of the mesenteric lymphovascular pedicle, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply gentle traction to the sigmoid colon while the mesentery is incised using electrocautery behind the superior rectal artery (SRA), which overlies the sacral promontory (",
"      <a class=\"graphic graphic_figure graphicRef56536 \" href=\"UTD.htm?43/21/44368\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Develop the avascular areolar tissue plane, located behind the SRA and anterior to the sacral promontory, laterally and diagonally over the pelvic brim.",
"     </li>",
"     <li>",
"      Perform the majority of the colon dissection with a gentle sweeping technique in the avascular plane. The colon is resected in a posterior to anterior motion to avoid injury to the underlying autonomic nerves and presacral venous plexus.",
"     </li>",
"     <li>",
"      Dissect in the avascular areolar tissue plane; a window is created and the ureters, gonadal and iliac vessels are identified and preserved (",
"      <a class=\"graphic graphic_figure graphicRef56536 \" href=\"UTD.htm?43/21/44368\">",
"       figure 6",
"      </a>",
"      ) The left and right ureters are retroperitoneal and cross the iliac vasculature near the origins of the internal iliac arteries; the left ureter enters the pelvis at the apex of the sigmoid mesocolon. Dissection of the pelvic portion of the ureters should be performed medially to laterally, as the blood supply enters laterally.",
"     </li>",
"     <li>",
"      Incise the mesentery cephalad over the anterior surface of the aorta; the first major branch is the inferior mesenteric artery (IMA) (",
"      <a class=\"graphic graphic_figure graphicRef73756 \" href=\"UTD.htm?40/32/41479\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Dissect the SRA to its origin from the IMA and ligate the SRA with a permanent tie suture (low tie method). This allows for removal of an appropriate amount of associated lymphatics for a rectal cancer resection (",
"      <a class=\"graphic graphic_figure graphicRef58219 \" href=\"UTD.htm?38/33/39448\">",
"       figure 5",
"      </a>",
"      ). An alternative to the low tie method is the high tie method, where the IMA is ligated at its origin. The authors prefer the low tie method because it preserves the blood supply from the IMA to the left colon (left colic artery), without compromising survival for rectal cancer patients compared with the high tie method [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Release the left colon from its lateral attachments by retracting the sigmoid and left colon medially and incising the line of Toldt (",
"      <a class=\"graphic graphic_figure graphicRef61720 \" href=\"UTD.htm?1/27/1456\">",
"       figure 7",
"      </a>",
"      ). The dissection is continued medially to the previously developed space.",
"     </li>",
"     <li>",
"      Divide the colon with a linear stapling device near the junction of the descending and sigmoid colon to facilitate distal resection and prevent bowel spillage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81824647\">",
"    <span class=\"h3\">",
"     Lateral to medial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lateral to medial approach is the traditional technique for mobilizing the colon in an open procedure. This technique includes the same principles for identifying and preserving the ureters, gonadal and iliac vessels, and ligating the SRA as described in the above section.",
"   </p>",
"   <p>",
"    Although this approach is more familiar to many surgeons, the disadvantages include potentially more blood loss from the early division of the lateral attachments prior to division of the vascular pedicles and more manipulation of the colon.",
"   </p>",
"   <p>",
"    The general principles for performing a left colectomy, beginning with mobilization of the left colon, include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Divide the lateral peritoneal attachments along the line of Toldt and mobilize the colon medially.",
"     </li>",
"     <li>",
"      Mobilize the IMA using blunt dissection in the avascular fusion plane.",
"     </li>",
"     <li>",
"      Identify the SRA as the artery passes into the pelvis at the base of the sigmoid mesentery.",
"     </li>",
"     <li>",
"      Mobilize the sigmoid colon and upper rectum in the avascular plane with a gentle sweeping posterior to anterior motion; the SRA is mobilized with the mesocolon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27176008\">",
"    <span class=\"h2\">",
"     Mobilization of rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobilization of the rectum is performed in the avascular presacral space between the fascia propria (the thin layer of fascia that encases the rectum and its lymphatics) and the presacral fascia (",
"    <a class=\"graphic graphic_figure graphicRef53546 \" href=\"UTD.htm?1/9/1174\">",
"     figure 8",
"    </a>",
"    ). Attention to detail is critical to avoid avulsion of the sacral plexus veins and middle sacral artery (",
"    <a class=\"graphic graphic_figure graphicRef76482 \" href=\"UTD.htm?6/4/6215\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general principles for mobilizing the upper rectum include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gently retract the upper rectum anteriorly to facilitate identification of the avascular presacral space, using either the operator&rsquo;s nondominant hand or a St. Mark&rsquo;s deep pelvic retractor (",
"      <a class=\"graphic graphic_picture graphicRef71451 \" href=\"UTD.htm?29/36/30274\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Identify and preserve the iliohypogastric nerves along either side of the rectum at the level of the sacral promontory (",
"      <a class=\"graphic graphic_figure graphicRef75983 \" href=\"UTD.htm?6/50/6952\">",
"       figure 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Access the retrorectal space posteriorly in the midline, using electrocautery to divide the rectorectal fascia (Waldeyer&rsquo;s fascia) (",
"      <a class=\"graphic graphic_figure graphicRef80416 \" href=\"UTD.htm?17/24/17807\">",
"       figure 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Precise dissection on the fascia propria reduces the risk of damage to the iliohypogastric nerves. Tethering from the lateral peritoneal reflexion is incised and divided. The lateral ligaments that contain the middle hemorrhoidal vascular pedicles are divided with electrocautery (",
"      <a class=\"graphic graphic_figure graphicRef84656 \" href=\"UTD.htm?26/35/27185\">",
"       figure 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68802 \" href=\"UTD.htm?1/53/1887\">",
"       figure 13",
"      </a>",
"      ). Circumferential dissection is completed by incising the peritoneum at the base of the cul-de-sac. Proceed with the dissection to the level of the pelvic diaphragm.",
"     </li>",
"     <li>",
"      Avoid injury to the posteriorly located parasympathetic fibers by using electrocautery judiciously when dissecting the posterior plane.",
"     </li>",
"     <li>",
"      Technical considerations when operating in the male pelvis (",
"      <a class=\"graphic graphic_figure graphicRef80126 \" href=\"UTD.htm?41/4/42051\">",
"       figure 14",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Incise the peritoneum approximately 5 mm anterior to the fold of the cul-de-sac, exposing the seminal vesicles that are cleared by sharp dissection with electrocautery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continue the plane of dissection anteriorly to encompass Denonvilliers&rsquo; fascia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/16\">",
"       16",
"      </a>",
"      ], until reaching the junction with the prostate capsule. For rectal cancers located anteriorly, Denonvilliers&rsquo; fascia is separated from the prostate capsule to provide a clear margin. For rectal cancers located posteriorly, the dissection is performed in the plane closer to the anterior surface of the rectum, leaving Denonvilliers&rsquo; fascia intact to preserve the nerves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Terminate the mobilization anteriorly below the level of the seminal vesicles and posteriorly at the upper border of the coccyx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical considerations when operating in the female pelvis (",
"      <a class=\"graphic graphic_figure graphicRef59561 \" href=\"UTD.htm?2/13/2259\">",
"       figure 15",
"      </a>",
"      ):",
"     </li>",
"     <li>",
"      Retract the uterus superiorly using a St. Mark&rsquo;s Retractor (",
"      <a class=\"graphic graphic_picture graphicRef71451 \" href=\"UTD.htm?29/36/30274\">",
"       picture 1",
"      </a>",
"      ) or by securing the uterus to the abdominal wall with a suture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Incise the peritoneum at the peritoneal reflection with electrocautery and dissect along the rectovaginal septum in the areolar tissue plane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the vaginal segment en-bloc if the tumor is tethered to the posterior wall of the vagina, the vaginal segment should be removed en-bloc with the rectal specimen. The posterior vagina is reconstructed with absorbable sutures during the perineal portion of the procedure (",
"      <a class=\"graphic graphic_figure graphicRef60890 \" href=\"UTD.htm?23/33/24086\">",
"       figure 16",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoid bearing in or coning the specimen during the circumferential dissection, as this will compromise the circumferential resection margin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Terminate the mobilization anteriorly below the cervix uteri and posteriorly at the upper border of the coccyx (",
"      <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"       figure 17",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Do not mobilize the mesorectum from the levator muscle at this time (",
"      <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"       figure 17",
"      </a>",
"      ). However, the bowel is divided at a level to permit at least a 5 cm margin proximal to the malignancy.",
"     </li>",
"     <li>",
"      The colostomy is constructed prior to performing the perineal resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11860333\">",
"    <span class=\"h2\">",
"     Colostomy construction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical principles of construction of an end colostomy, including technical insights and use of prophylactic mesh are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link\">",
"     \"Surgical principles of ostomy construction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791179\">",
"    <span class=\"h2\">",
"     Repositioning for perineal resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the completion of the abdominal portion of the operation, the patient is repositioned from the modified dorsal lithotomy to the prone position for the perineal portion of the procedure. The boots are removed and the legs are slowly lowered to the operating table simultaneously. This will avoid injury to the hips from inadvertent rotation. The patient is now supine in preparation to be transferred to the prone (Kraske) jackknife position (",
"    <a class=\"graphic graphic_figure graphicRef70624 \" href=\"UTD.htm?0/29/464\">",
"     figure 18",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31823231\">",
"    <span class=\"h3\">",
"     Cylindrical versus conventional approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perineal resection of the rectum and anus and adjacent tissues (",
"    <a class=\"graphic graphic_figure graphicRef74060 \" href=\"UTD.htm?28/57/29588\">",
"     figure 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79236 \" href=\"UTD.htm?14/47/15093\">",
"     figure 20",
"    </a>",
"    ) was traditionally performed in the lithotomy position; however, that approach is associated with a high rate of positive circumferential resection margins (CRM), intra-operative bowel perforation, and local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contemporary approach is to place the patient in the prone jackknife (Kraske) position, which facilitates a cylindrical perineal resection. A randomized trial of 67 patients undergoing an APR found that patients resected using the cylindrical approach had a lower rate of positive circumferential resection margins compared with patients undergoing the conventional (lithotomy) approach (5.7 versus 28.1 percent, p = 0.013) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients undergoing the cylindrical approach had a statistically similar probability of intra-operative bowel perforation (2 of 35 versus 5 of 32 patients, p = 0.246), but a significantly higher median three and six month postoperative visual analogue score (VAS) for pain (VAS 4 versus 1, and 3 versus 0, respectively). In addition, a retrospective review of 109 patients with a potentially curable primary adenocarcinoma found that patients treated by the cylindrical approach (n = 10) had significantly fewer intra-operative perforations compared with patients resected in the lithotomy position (3.7 versus 22.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients undergoing the cylindrical approach also had fewer positive circumferential resection margins (14.8 versus 40.6 percent).",
"   </p>",
"   <p>",
"    Rationale for the improved results with the cylindrical approach to a perineal resection includes more tissue excised [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/21\">",
"     21",
"    </a>",
"    ] and the surgeon is more likely to perform the resection in the appropriate tissue plane [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/18\">",
"     18",
"    </a>",
"    ]. The disadvantages of the prone jackknife position include anesthetic-related complications (eg, displacement of the endotracheal tube, decreased cardiac index) and direct pressure injuries (eg, skin necrosis, peripheral nerve injury).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174131\">",
"    <span class=\"h2\">",
"     Perineal resection",
"    </span>",
"   </p>",
"   <p>",
"    The general principles for performing the perineal resection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tape the buttocks apart and close the anus with a silk purse string suture.",
"     </li>",
"     <li>",
"      Make an incision around the anus, extending to the lower edge of the sacrum.",
"     </li>",
"     <li>",
"      Dissect through the subcutaneous adipose tissue just outside the plane of the external sphincter (",
"      <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"       figure 17",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79445 \" href=\"UTD.htm?41/60/42945\">",
"       figure 21",
"      </a>",
"      ), using electrocautery and a self-retaining retractor (eg, Lone Star retractor system&trade;) to optimize exposure and access.",
"     </li>",
"     <li>",
"      Identify the levator muscle and dissect to the point of insertion of the muscle on the pelvic sidewall (",
"      <a class=\"graphic graphic_figure graphicRef63229 \" href=\"UTD.htm?10/37/10837\">",
"       figure 22",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general principles for closure of the perineal wound after resection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The perineal wound is closed in layers with a series of 2-0 absorbable sutures used to approximate the subcutaneous adipose tissue.",
"     </li>",
"     <li>",
"      An absorbable subcuticular suture is used to close the skin. In the majority of cases, we close the skin primarily.",
"     </li>",
"     <li>",
"      For defects too large for a primary closure, the perineal defect is reconstructed with a myocutaneous flap, such as a pedicled gluteus maximus, gracilis, or rectus abdominal flap [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. There is no consensus for the optimal flap for immediate repair of the pelvic defect. In a retrospective review of 133 patients undergoing an APR or pelvic exenteration for cancer resection, patients with a perineal defect closed with a vertical rectus abdominis myocutaneous flap (VRAM, n=114) had significantly fewer major complications compared with closure with a gracilis flap (15 versus 42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients with a VRAM closure also had fewer rates of donor cellulitis (6 versus 26 percent), pelvic abscesses (6 versus 32 percent), and wound dehiscence (5 versus 21 percent). Harvesting VRAM flaps did not increase early abdominal wall complications. The decision on the type of flap formation will be influenced by patient factors (current smoker, lifestyle factors), tumor factors (neoadjuvant therapy, size of defect to be repaired) and operative expertise in the unit offering the surgery.",
"     </li>",
"     <li>",
"      The authors do not drain the perineum; however, other surgeons may opt to use closed suction drains. Definitive evidence from high-quality randomized trials is not available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4585?source=see_link&amp;anchor=H392080646#H392080646\">",
"       \"Management of perineal complications following an abdominal perineal resection\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174145\">",
"    <span class=\"h1\">",
"     INTRA-OPERATIVE CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of the rectum is associated with several technical challenges, including preservation of the ureters and urethra, sacral venous plexus, and pelvic autonomic nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174972\">",
"    <span class=\"h2\">",
"     Ureter and urethra",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ureter is at risk for transection or injury during the lateral mobilization of the colon and ligation of the superior rectal artery during the abdominal portion of the operation, while the urethra is at risk when performing the anterior portion of the perineal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following key points and maneuvers help identify and preserve the ureters [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ureter never branches.",
"     </li>",
"     <li>",
"      The ureter shows evidence of peristalsis or vermiculation when manipulated.",
"     </li>",
"     <li>",
"      If the ureter cannot be identified distally due to inflammation or tumor, identify a more proximal portion and dissect distally.",
"     </li>",
"     <li>",
"      Avoid excessive dissection of the ureter to preserve blood supply and avert ischemic necrosis.",
"     </li>",
"     <li>",
"      Place ureteral stents prior to resection, particularly in settings of large cancers, or previous pelvic surgery or inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Identify all structures prior to division and ligation. Vascular ligation (eg, superior rectal artery) should not be performed prior to identification of the ureters.",
"     </li>",
"     <li>",
"      Palpate the indwelling urinary catheter to define the plane between the prostate and the rectum. The urethra is at risk of injury with anterior rectal tumors that require the resection of the prostate gland. If a urethral injury has occurred, then the catheter is typically visible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of transection or other injury to the ureters is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43655?source=see_link\">",
"     \"Surgical repair of an iatrogenic ureteral injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H12351061#H12351061\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Pelvic and genitourinary injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174153\">",
"    <span class=\"h2\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening hemorrhage can be encountered during the pelvic dissection and typically arises from injury to the presacral plexus or internal iliac vessels (",
"    <a class=\"graphic graphic_figure graphicRef52520 \" href=\"UTD.htm?27/45/28375\">",
"     figure 23",
"    </a>",
"    ). In the setting of bleeding from the presacral plexus, the first step is to apply pressure to the area and advise the anesthesiologist so blood products can be administered. Titanium thumbtacks can be used to directly compress the bleeding vein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/29\">",
"     29",
"    </a>",
"    ]. If local control measures fail, the pelvis is packed with laparotomy sponges, the procedure is terminated, and resuscitation is continued in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The pH, intravascular volume, and clotting status must be optimized prior to returning to the operating room, typically in 24 to 48 hours, to remove the packs and complete the planned procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If bleeding is from the internal iliac vessels, the first step is to obtain control by direct pressure proximally and distally and determine the source of the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25128/abstract/32\">",
"     32",
"    </a>",
"    ]. It is prudent to consult a vascular surgeon, if available. If a repair is unfeasible, or if the patient is becoming unstable, both the internal iliac artery and vein can be ligated if necessary.",
"   </p>",
"   <p>",
"    Management of bleeding complications following colon and rectal operations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H12351613#H12351613\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Major vessel injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H98515550#H98515550\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Presacral bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791591\">",
"    <span class=\"h2\">",
"     Pelvic autonomic nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pelvic autonomic nerves consist of sympathetic and parasympathetic components that regulate urinary and sexual function (",
"    <a class=\"graphic graphic_figure graphicRef56679 \" href=\"UTD.htm?10/7/10362\">",
"     figure 24",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63993 \" href=\"UTD.htm?1/36/1607\">",
"     figure 25",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Injury to the nerves can occur during the following steps of the operation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sympathetic nerves are at risk of injury at their origin from the aortic plexus during ligation of the internal mesenteric artery (IMA) and at the sacral promontory during the division of the hypogastric nerves from the hypogastric plexus.",
"     </li>",
"     <li>",
"      The parasympathetic nerves are at risk of injury during the lateral dissection, especially during the division of the lateral ligaments and anterolaterally during the dissection behind the prostate and seminal vesicles.",
"     </li>",
"     <li>",
"      Interlacing sympathetic and parasympathetic nerve fibers from the pelvic plexus form the inferior hypogastric nerve plexus that innervates the rectum, bladder, ureter, prostate, seminal vesicles, and corpora cavernosa, and are at risk when dissecting the rectum from these structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Damage to these autonomic nerves can lead to bladder and sexual dysfunction and is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H98515606#H98515606\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Genitourinary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27176130\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are managed by the fast-track multimodal protocol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=see_link\">",
"     \"Fast-track protocols in colorectal surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=see_link&amp;anchor=H186830109#H186830109\">",
"     \"Right and extended right colectomy: Open technique\", section on '\"Fast track\" Postoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of the colostomy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of patients with a colostomy or ileostomy\", section on 'Permanent colostomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27176137\">",
"    <span class=\"h1\">",
"     PERINEAL WOUND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perineal wound complications are common. The incidence, risks, and management are discussed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4585?source=see_link\">",
"     \"Management of perineal complications following an abdominal perineal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27174899\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal perineal resection (APR) includes the resection of the sigmoid colon, rectum, and anus and the construction of a permanent end colostomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for an APR include benign conditions (eg, Crohn&rsquo;s proctitis) and malignancy (eg, low rectal cancers, recurrent anal cancers). (See",
"      <a class=\"local\" href=\"#H27174907\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative assessment includes an evaluation by an enterostomal nurse, mechanical bowel preparation at the discretion of the surgeon, prophylactic antibiotics, and deep vein thrombosis prophylaxis. (See",
"      <a class=\"local\" href=\"#H27174058\">",
"       'Preoperative preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The authors mobilize the colon using the medial to lateral approach by ligating the lymphovascular pedicle prior to mobilizing the colon. (See",
"      <a class=\"local\" href=\"#H27176001\">",
"       'Mobilization of colon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mobilization of the rectum is performed in the avascular presacral space between the fascia propria (the thin layer of fascia that encases the rectum and its lymphatics) and the presacral fascia. Attention to detail is critical to avoid avulsion of the sacral plexus veins and middle sacral artery. (See",
"      <a class=\"local\" href=\"#H27176008\">",
"       'Mobilization of rectum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The perineal resection should be performed in the prone (Kraske) jackknife position to facilitate the perineal resection. (See",
"      <a class=\"local\" href=\"#H27174131\">",
"       'Perineal resection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/1\">",
"      Contant CM, Hop WC, van't Sant HP, et al. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. Lancet 2007; 370:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/2\">",
"      Van't Sant HP, Weidema WF, Hop WC, et al. The influence of mechanical bowel preparation in elective lower colorectal surgery. Ann Surg 2010; 251:59.",
"     </a>",
"    </li>",
"    <li>",
"     Bretagnol F, Panis Y, Rullier E, et al. Rectal cancer surgery without boewl preparation. The French GRECAR III multicenter, single-blinded, randomized trial. Presented at ASCRS 2011, Vancouver, British Columbia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/4\">",
"      Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 1996; 78:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/5\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/6\">",
"      O'Connell MP. Positioning impact on the surgical patient. Nurs Clin North Am 2006; 41:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/7\">",
"      Stephenson LL, Webb NA, Smithers CJ, et al. Lateral femoral cutaneous neuropathy following lateral positioning on a bean bag. J Clin Anesth 2009; 21:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/8\">",
"      Recommended practices for positioning the patient in the perioperative setting. Perioperative Standards and Recommended Practices. AORN J 2008; :497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/9\">",
"      Sawyer RJ, Richmond MN, Hickey JD, Jarrratt JA. Peripheral nerve injuries associated with anaesthesia. Anaesthesia 2000; 55:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/10\">",
"      Dybec RB. Intraoperative positioning and care of the obese patient. Plast Surg Nurs 2004; 24:118.",
"     </a>",
"    </li>",
"    <li>",
"     Sonoda T, Milsom JW.  Section 5: Gastrointestinal tract and abdomen. Chapter 34: Segmental colon resection.ACS Surgery: Principles and Practice file://www.acssurgery.com/acs/chapters/ch0534.htm (Accessed on November 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/12\">",
"      Titu LV, Tweedle E, Rooney PS. High tie of the inferior mesenteric artery in curative surgery for left colonic and rectal cancers: a systematic review. Dig Surg 2008; 25:148.",
"     </a>",
"    </li>",
"    <li>",
"     Chapter 83. Abdominoperineal resection, Low anterior resection. In: Operative anatomy, Third, Scott-Conner CE, Dawson DL.  (Eds), Wolters Kluwer, Lippincott, Williams &amp; Wilkins, Philadelphia 2009. p.569.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/14\">",
"      Jin ZM, Peng JY, Zhu QC, Yin L. Waldeyer's fascia: anatomical location and relationship to neighboring fasciae in retrorectal space. Surg Radiol Anat 2011; 33:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/15\">",
"      Garc&iacute;a-Armengol J, Garc&iacute;a-Botello S, Martinez-Soriano F, et al. Review of the anatomic concepts in relation to the retrorectal space and endopelvic fascia: Waldeyer's fascia and the rectosacral fascia. Colorectal Dis 2008; 10:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/16\">",
"      Lindsey I, Guy RJ, Warren BF, Mortensen NJ. Anatomy of Denonvilliers' fascia and pelvic nerves, impotence, and implications for the colorectal surgeon. Br J Surg 2000; 87:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/17\">",
"      West NP, Finan PJ, Anderin C, et al. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol 2008; 26:3517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/18\">",
"      Nagtegaal ID, van de Velde CJ, Marijnen CA, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005; 23:9257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/19\">",
"      Han JG, Wang ZJ, Wei GH, et al. Randomized clinical trial of conventional versus cylindrical abdominoperineal resection for locally advanced lower rectal cancer. Am J Surg 2012; 204:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/20\">",
"      Bernstein TE, Endreseth BH, Romundstad P, et al. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009; 96:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/21\">",
"      Marr R, Birbeck K, Garvican J, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005; 242:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/22\">",
"      Holm T, Ljung A, H&auml;ggmark T, et al. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg 2007; 94:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/23\">",
"      Galandiuk S, Jorden J, Mahid S, et al. The use of tissue flaps as an adjunct to pelvic surgery. Am J Surg 2005; 190:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/24\">",
"      Shibata D, Hyland W, Busse P, et al. Immediate reconstruction of the perineal wound with gracilis muscle flaps following abdominoperineal resection and intraoperative radiation therapy for recurrent carcinoma of the rectum. Ann Surg Oncol 1999; 6:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/25\">",
"      Nelson RA, Butler CE. Surgical outcomes of VRAM versus thigh flaps for immediate reconstruction of pelvic and perineal cancer resection defects. Plast Reconstr Surg 2009; 123:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/26\">",
"      Elliott SP, McAninch JW. Ureteral injuries: external and iatrogenic. Urol Clin North Am 2006; 33:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/27\">",
"      Fry DE, Milholen L, Harbrecht PJ. Iatrogenic ureteral injury. Options in management. Arch Surg 1983; 118:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/28\">",
"      Redan JA, McCarus SD. Protect the ureters. JSLS 2009; 13:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/29\">",
"      Timmons MC, Kohler MF, Addison WA. Thumbtack use for control of presacral bleeding, with description of an instrument for thumbtack application. Obstet Gynecol 1991; 78:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/30\">",
"      Loveland JA, Boffard KD. Damage control in the abdomen and beyond. Br J Surg 2004; 91:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/31\">",
"      McPartland KJ, Hyman NH. Damage control: what is its role in colorectal surgery? Dis Colon Rectum 2003; 46:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25128/abstract/32\">",
"      Oderich GS, Panneton JM, Hofer J, et al. Iatrogenic operative injuries of abdominal and pelvic veins: a potentially lethal complication. J Vasc Surg 2004; 39:931.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14995 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25128=[""].join("\n");
var outline_f24_34_25128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27174899\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27174051\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27174907\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27174058\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27174986\">",
"      Enterostomal assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27174073\">",
"      Mechanical bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73475483\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27175479\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27174094\">",
"      OPEN SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27174103\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27175928\">",
"      Exploration for resectability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27176001\">",
"      Mobilization of colon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81824639\">",
"      - Medial to lateral approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81824647\">",
"      - Lateral to medial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27176008\">",
"      Mobilization of rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11860333\">",
"      Colostomy construction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791179\">",
"      Repositioning for perineal resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31823231\">",
"      - Cylindrical versus conventional approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27174131\">",
"      Perineal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27174145\">",
"      INTRA-OPERATIVE CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27174972\">",
"      Ureter and urethra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27174153\">",
"      Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791591\">",
"      Pelvic autonomic nerves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27176130\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27176137\">",
"      PERINEAL WOUND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27174899\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14995|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/19/36148\" title=\"figure 1\">",
"      Abdominal perineal resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/56/22403\" title=\"figure 2\">",
"      Nerves prone to stretch or compression in lithotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/32/41479\" title=\"figure 3\">",
"      Blood supply to the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3127\" title=\"figure 4\">",
"      Venous drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/33/39448\" title=\"figure 5\">",
"      Lymphatic drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/21/44368\" title=\"figure 6\">",
"      Dissection of colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/27/1456\" title=\"figure 7\">",
"      Mobilization of the left colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/9/1174\" title=\"figure 8\">",
"      Blood supply and lymph nodes of the rectum and upper anal canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/4/6215\" title=\"figure 9\">",
"      Blood supply of the pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/50/6952\" title=\"figure 10\">",
"      Lumbosacral plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/24/17807\" title=\"figure 11\">",
"      Mobilization of the upper rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/35/27185\" title=\"figure 12\">",
"      Proctocolectomy for cancer and division of lateral ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/53/1887\" title=\"figure 13\">",
"      Lateral rectal ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/4/42051\" title=\"figure 14\">",
"      Male pelvis - Sagittal section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/13/2259\" title=\"figure 15\">",
"      Female pelvis - Sagittal view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/33/24086\" title=\"figure 16\">",
"      Paravaginal defect repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/54/21348\" title=\"figure 17\">",
"      Anal rectal anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/29/464\" title=\"figure 18\">",
"      Kraske prone jacknife position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/57/29588\" title=\"figure 19\">",
"      Female perineum muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/47/15093\" title=\"figure 20\">",
"      Male perineum muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/60/42945\" title=\"figure 21\">",
"      Perineal resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/37/10837\" title=\"figure 22\">",
"      Anatomy of the ischiorectal fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/45/28375\" title=\"figure 23\">",
"      Anatomy of the presacral venous plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/7/10362\" title=\"figure 24\">",
"      Pelvic nerve plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/36/1607\" title=\"figure 25\">",
"      Nerves of the female pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14995|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/36/30274\" title=\"picture 1\">",
"      St Marks deep pelvic retractor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 2\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=related_link\">",
"      Fast-track protocols in colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4585?source=related_link\">",
"      Management of perineal complications following an abdominal perineal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=related_link\">",
"      Operating room safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=related_link\">",
"      Right and extended right colectomy: Open technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43655?source=related_link\">",
"      Surgical repair of an iatrogenic ureteral injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25129="Overview of hematopoiesis and stem cell function";
var content_f24_34_25129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hematopoiesis and stem cell function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25129/contributors\">",
"     Colin A Sieff, MB, BCh, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25129/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25129/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/34/25129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circulating blood cells are formed in bone marrow through a process called hematopoiesis. The bone marrow has an enormous production capacity; it is estimated that 10",
"    <sup>",
"     10",
"    </sup>",
"    erythrocytes and 10",
"    <sup>",
"     8",
"    </sup>",
"    to 10",
"    <sup>",
"     9",
"    </sup>",
"    leukocytes are produced per hour in the steady state. Furthermore, while cell numbers are maintained within fairly narrow limits in normal subjects, they can be greatly amplified on demand.",
"   </p>",
"   <p>",
"    These huge cell numbers are immediate descendants of maturing precursors that arise from a smaller pool of progenitors. The progenitors in turn arise from an even smaller pool of hematopoietic stem cells (HSC) that are thought to be mostly in a resting or nondividing state and have the capacity to self-renew (and thus maintain their numbers).",
"   </p>",
"   <p>",
"    Hematopoietic stem cells are multipotent and have the capacity to differentiate into the cells of all 10 blood lineages &mdash; erythrocytes, platelets, neutrophils, eosinophils, basophils, monocytes, T and B lymphocytes, natural killer cells, and dendritic cells (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BONE MARROW ANATOMY AND MICROENVIRONMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;To develop and differentiate, hematopoietic progenitor cells require both cellular and soluble growth factor support. The cellular elements are provided by the surrounding bone, bone marrow stroma, and the microenvironment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microenvironment of the marrow cavity is a vast network of vascular channels or sinusoids between which float fronds of hematopoietic cells, including fat cells. Reticular fibroblastoid cells form the adventitial surfaces of the vascular sinuses and extend cytoplasmic processes to create a lattice on which blood cells are found. The lattice itself can be demonstrated by reticulin stains of marrow sections, while the conformation of the meshwork of reticulin and the location of hematopoietic cells in the network of vascular sinuses is illustrated by scanning electron microscopy.",
"   </p>",
"   <p>",
"    The stem and progenitor cells are supported by stromal cells that comprise fibroblastoid cells, endothelial cells, and macrophages; these cells provide cell-cell contact support to HSC. The fibroblastoid network provides two major functions &mdash; an adhesive framework onto which the developing cells are bound, and the production of essential hematopoietic growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/9\">",
"     9",
"    </a>",
"    ]. Along with T lymphocytes, these cells produce a variety of hematopoietic growth factors or cytokines that are thought to support the survival, proliferation, and differentiation of HSC and progenitors. Hematopoietic stem cells (HSCs) are found in two distinct niches: an endosteal niche where HSCs lie in close proximity to a subset of spindle-shaped, N-cadherin + osteoblasts; and a vascular niche lined by sinusoidal endothelial cells. The endosteal niche is thought to be important for the regulation of HSC self-renewal, while the vascular niche is important for proliferation, differentiation, and mobilization.",
"   </p>",
"   <p>",
"    The marrow circulation comprises central and radial arteries that ramify in the cortical capillaries, join the marrow sinusoids, and drain into the central sinus. Cells egress from the marrow sinusoids into the venous circulation through concomitant veins. The inner, or luminal, surface of the vascular sinusoids is lined with endothelial cells, the cytoplasmic extensions of which overlap, or interdigitate, with one another. The escape of developing hematopoietic cells into the sinus for transport to the general circulation occurs through gaps that develop in this endothelial lining and even through endothelial cell cytoplasmic pores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of experiments led to the demonstration of the pluripotent stem cell. The concept that sustained hematopoiesis comes from pluripotent stem cells derives from the observation that mice can be protected from the lethal effects of whole body irradiation by exteriorization and shielding of the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/10\">",
"     10",
"    </a>",
"    ]. This protective effect was shown to be cell-mediated as the injection of spleen cells could initiate recovery and reestablish hematopoiesis in irradiated animals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compatible with the hypothesis of the clonal nature of hematopoiesis and the concept that a single pluripotent stem cell has the capacity to repopulate the entire hematopoietic system was the demonstration that colonies of murine hematopoietic cells could be observed in the spleen of irradiated, transplanted recipients within 10 days after the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/12\">",
"     12",
"    </a>",
"    ]. These spleen colony-forming units (CFU-S) generated colonies that contained precursors to erythrocytes, granulocytes and macrophages, and megakaryocytes.",
"   </p>",
"   <p>",
"    Subsequent experiments using karyotypically marked donor cells confirmed the clonal origin of the differentiated cells in the colony, proving that a single pluripotent stem cell had given rise to these differentiated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/13\">",
"     13",
"    </a>",
"    ]. It was also shown that each colony that formed at day 12 after transplantation (CFU-S12) contained a number of cells that could again form a colony of differentiated progeny in a second irradiated recipient, demonstrating their self-renewal capacity; in contrast, spleen colonies that form on day eight (CFU-S8) have only myeloerythroid potential.",
"   </p>",
"   <p>",
"    The demonstration of a pluripotent stem cell in adult bone marrow led to a systematic search for the ontogenic origins of HSC. In mammals, hematopoiesis occurs sequentially in the yolk sac, an intraembryonic",
"    <span class=\"nowrap\">",
"     aorta/gonad/mesonephros",
"    </span>",
"    (AGM) region, fetal liver, placenta, and finally the bone marrow. Whether HSC first arise in the yolk sac or AGM region is still controversial. The observation that cells with long-term repopulating (LTR)-HSC activity arise first in the AGM region and not in yolk sac or other intraembryonic regions suggested that HSC form first within the embryo proper [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, classic studies by Metcalf and Moore [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/16\">",
"     16",
"    </a>",
"    ] showed that hematopoiesis does not occur in fetal liver if the yolk sac is removed on day 7.5, and HSC-like cells can be detected as early as day 9 in murine yolk sac [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/17\">",
"     17",
"    </a>",
"    ]. Runx1, a transcription factor that is important for HSC development is expressed only in yolk sac at day 7.5. Transgenic cell tracing experiments show that these day 7.5 Runx1+ cells eventually mark cells in fetal liver and adult hematopoietic sites, suggesting that the yolk sac is indeed the origin of adult HSC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stem cells in other tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stem cell model of hematopoiesis has parallels in other organ systems. That rapidly self-renewing epithelial tissues like skin and intestine have stem cells that continually replenish the cells lost by differentiation is well described. However, the demonstration of the existence of neural stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] has raised the possibility that many organ systems might retain a population of self-renewing stem cells. Muscle satellite cells also appear to fulfill this role. These organ or tissue specific stem cells arise during early fetal development from embryonic stem cells of the inner cell mass of the blastocyst that are totipotent and give rise to all body cell types. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Mysenchymal stem cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Identification of stem and progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cells are identified by a number of assays. The factors that regulate production are not completely understood but include a variety of humoral or marrow stroma derived regulators.",
"   </p>",
"   <p>",
"    Maturing precursors and mature cells are recognizable under a microscope. In contrast, progenitors and stem cells are morphologically indistinguishable, and functional assays or identification of surface antigenic characteristics are required to detect their presence. Progenitor cells will form colonies of maturing cells of different lineages if they are immobilized in a semisolid medium, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    or agar and stimulated with growth factors. They are often collectively referred to as colony forming cells (CFC) or units (CFU). Examples of growth factors include (",
"    <a class=\"graphic graphic_table graphicRef57050 \" href=\"UTD.htm?17/4/17483\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stem cell factor (SCF, also called Steel factor or KIT ligand) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/21\">",
"       21",
"      </a>",
"      ], interleukin-3 (IL-3), and erythropoietin (EPO) drive the proliferation and maturation of primitive erythroid burst-forming units (BFU-E); the more mature erythroid colony-forming units (CFU-E) are entirely EPO dependent for their first few divisions.",
"     </li>",
"     <li>",
"      SCF,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) drive the development of granulocyte and macrophage colony-forming units (CFU-GM).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     In vitro assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many in vitro assays that measure functions characteristic of stem cells have been proposed as surrogate stem cell assays but, until homogeneous populations can be evaluated in both in vitro and in vivo transplantation assays, it will be impossible to determine the precise cell type measured by these methods. Multipotency is demonstrated by colonies in semisolid media that contain granulocytes, erythrocytes, monocytes and megakaryocytes (CFU-GEMM) in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    cultures of human bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. A unique type of in vitro blast cell colony that comprises small numbers of blast cells with higher self-renewal capacity (secondary colonies on replating) than CFU-GEMM has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for the presence of pluripotent hematopoietic stem cells is also derived from the human \"Dexter\" technique [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/27\">",
"     27",
"    </a>",
"    ] for liquid culture of marrow in which myeloid progenitors (mostly CFU-GM) are sustained for about two months on and within an adherent stromal monolayer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The progenitors can be detected by replating into",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    with several growth factors at five to eight weeks, thereby demonstrating that both unipotent and multipotent cells are generated in this culture system.",
"   </p>",
"   <p>",
"    This long term culture technique has been adapted to a limiting dilution assay in which long-term culture initiating cells (LTC-IC) can be quantitated after culture at different concentrations on a stromal layer for five weeks followed by replating in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    to score for the number of wells that do not contain colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/30\">",
"     30",
"    </a>",
"    ]. An analogous cobblestone area forming cell (CAFC) assay has also been adapted to human cells by counting proliferating clones directly in the stromal layer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/31\">",
"     31",
"    </a>",
"    ]; the areas of active hematopoiesis have a \"cobblestone\" appearance. Last, an assay that measures the enormous proliferative capacity of primitive progenitor cells is the high proliferative potential colony forming cell (HPP-CFC) assay, that gives rise to macroscopically (&gt;5 mm) visible colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these in vitro assays measure properties attributable to stem cells such as pluripotency or great proliferative capacity, they cannot address the essential property of the ability of HSC to reconstitute long-term hematopoiesis. This property ideally requires an in vivo transplantation assay. A competitive repopulation assay, based upon transplanting an unknown stem cell population together with a standard dose of competing cells into irradiated recipient mice, has been developed in the mouse to quantitate murine HSC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, human HSC populations can be injected into severe combined immunodeficient (SCID or",
"    <span class=\"nowrap\">",
"     NOD/SCID)",
"    </span>",
"    mice which are monitored six to eight weeks later for evidence of human engraftment in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is believed that this SCID repopulating cell (SRC) represents a cell closer to the HSC than cells measured in in vitro assays [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/35\">",
"     35",
"    </a>",
"    ]. A tentative relationship of the cells measured in these different assays of stem and progenitor cells is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef77910 \" href=\"UTD.htm?1/33/1567\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cell surface antigenic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell surface characteristics have been used to purify or define populations of cells that include stem cells and progenitors. For humans, the most frequently used markers are the CD34 antigen, expressed on HSC and progenitors, and CD38, expressed on a subset of more mature progenitors and on maturing cells, but",
"    <strong>",
"     not",
"    </strong>",
"    on stem cells.",
"   </p>",
"   <p>",
"    The most primitive human hematopoietic cells are CD34+ and CD38- [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, CD34+ cells comprise approximately 2 to 5 percent of nucleated cells in bone marrow, while HSC are much rarer (about 1 per 20,000 bone marrow cells). Thus, while markers such as CD34 are useful to enrich for primitive cells, their presence is only an indirect indication of the presence of HSC.",
"   </p>",
"   <p>",
"    Addition of antibodies to other cell surface proteins expressed on HSC such as CD133, KIT, or CD150, in combination with exclusion of cells that express lineage markers (Lin-) can result in much greater enrichment of LT-HSC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Using the",
"    <span class=\"nowrap\">",
"     NOD/SCID",
"    </span>",
"    mouse model, human hematopoiesis could be expressed in mouse marrow by",
"    <span class=\"nowrap\">",
"     CD34+/CD38-/lin-",
"    </span>",
"    cells expressing",
"    <span class=\"nowrap\">",
"     Flk2/Flt3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/42\">",
"     42",
"    </a>",
"    ]. Infusion of similar cells that were",
"    <span class=\"nowrap\">",
"     Flk2/Flt3",
"    </span>",
"    negative did not result in successful engraftment.",
"   </p>",
"   <p>",
"    Other cell characteristics that have been used to define HSC populations include the ability to extrude vital dyes such as Rhodamine 123 (Rh-123-low) and Hoechst 33342 (side population cells), and aldehyde dehydrogenase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low-intensity fluorescence Rh-123 discriminates a quiescent hematopoietic stem cell population in bone marrow, which provides stable, long-term hematopoiesis after transplantation. Rh-123 labels mitochondria with increasing intensity proportional to cellular activation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experiments using",
"    <span class=\"nowrap\">",
"     KIT+/lin-",
"    </span>",
"    cells or the Hoechst dye have raised the possibility that murine, primate and human HSC capable of long term reconstitution may be found in a CD34- fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. This possibility is controversial, however, since experimental and transplantation data suggest that HSC do express CD34 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. Two other studies have presented evidence that CD34 negative cells, isolated by monoclonal antibodies, have engraftment potential and marrow repopulating capacity in immune deficient animals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The significance of these studies for human bone marrow transplantation awaits the identification of a marker for positive selection of these cells and the demonstration that they can repopulate human marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/49,57\">",
"     49,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STEM CELL HETEROGENEITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have provided a model of the stem cell compartment in which there is a continuum of cells with decreasing capacities for self-renewal, increasing likelihood for differentiation, and increasing proliferative activity. Cells progress in a unidirectional fashion in this continuum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is the most primitive cells with the greatest self-renewal capacity that reconstitute long-term hematopoiesis after transfer into irradiated recipient mice. These cells, termed long-term reconstituting hematopoietic stem cells (LTR-HSC), can be separated from committed progenitors (CFU-GM) and from CFU-S12 by countercurrent elutriation, and are unable to confer short-term radioprotection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, purification of murine HSC on the basis of surface antigen expression (Thy-1.1-low,Lin-,Sca-1+) and Rh-123-low has shown that as few as five cells can confer long-term repopulation, but that heterogeneity is still present, since cells with LTR-HSC activity alone or with both LTR-HSC and short-term reconstitution potentials reside in this cell fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/61\">",
"     61",
"    </a>",
"    ]. Most cells with short-term radioprotection capacity are likely to express the same cell surface antigens (Thy-1.1-low,Lin-,Sca-1+) but stain more brightly with Rh-123 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STEM CELL REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formed elements of the blood in vertebrates, including humans, continuously undergo replacement to maintain a constant number of red cells, white cells, and platelets. The number of cells of each type is maintained within a narrow range in the physiologically normal adult individual &mdash; approximately 5000 granulocytes, 5 x 10(6) red blood cells, and 150,000 to 300,000 platelets per microliter of whole blood. Regulatory mechanisms that maintain a balanced production of new blood cells are far from completely understood, but present evidence strongly supports the following basic principles (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single pluripotent stem cell is capable of giving rise to many committed progenitor cells, differentiated recognizable precursors of the specific types of blood cells, and mature cells by clonal proliferation. Furthermore, most pluripotent stem cells are quiescent, and hematopoiesis appears to be sustained in the steady state by the progeny of only a small number of activated stem cells. The \"clonal succession\" hypothesis that a series of stem cells may contribute clones successively to maintain hematopoiesis throughout the life span of an individual is an attractive explanation for the existence of \"active\" and \"resting\" stem cell clones, and has strong but not unequivocal experimental support [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/64\">",
"       64",
"      </a>",
"      ]. In vivo labeling data with bromodeoxyuridine (brdU) suggest that approximately 8 percent of murine stem cells enter the cell cycle every day [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/65\">",
"       65",
"      </a>",
"      ], making it appear more likely that stem cells regularly make the transition from a resting to an activated state.",
"     </li>",
"     <li>",
"      The pluripotent stem cell is capable of self-renewal, but this property may not be unlimited [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/61,66,67\">",
"       61,66,67",
"      </a>",
"      ]. Instead, the potential of HSC to self-renew is finite, determined by replicative history [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/68,69\">",
"       68,69",
"      </a>",
"      ] and perhaps also by accumulation of damage to DNA [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/70\">",
"       70",
"      </a>",
"      ]. In addition to their limited proliferative potential, committed progenitors also \"die by differentiation\", and their numbers depend upon influx from the pluripotent stem cell pool [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Committed progenitor cells are capable of response to humoral or marrow stroma derived regulators, some produced in reaction to the circulating levels of a particular differentiated cell type. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"       \"Regulation of erythropoiesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link\">",
"       \"Regulation of myelopoiesis\"",
"      </a>",
"      .) In this response, the progenitor cells proliferate and differentiate to form the recognizable blood cells. Under this type of control, amplification of production occurs at the committed progenitor cell level. There is evidence that committed progenitors can self-renew. For example, BFU-E can increase in number under the influence of glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/72\">",
"       72",
"      </a>",
"      ], which may underlie the rapid increase in erythropoiesis during stress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the regulatory molecules are produced by hematopoietic accessory cells in close proximity to progenitor cells. These molecules are produced as part of an incompletely understood complex regulatory network operating at close range and may involve accessory cell-progenitor cell interactions. As an example, ectopic expression of G-CSF receptors in progenitor cells supports G-CSF dependent differentiation of these cells into mature granulocytes, macrophages, megakaryocytes and erythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/73\">",
"     73",
"    </a>",
"    ]. The cytoplasmic domain of the receptor is not necessary for this interaction since similar effects are produced by G-CSF when a chimeric receptor containing the extracellular and transmembrane domains of the G-CSF receptor fused to the cytoplasmic domain of the erythropoietin receptor is substituted for G-CSF receptor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic differentiation requires an appropriate microenvironment. In normal humans, this environment is confined to the bone marrow [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/4\">",
"       4",
"      </a>",
"      ], whereas in the mouse the microenvironment includes both the spleen and bone marrow. Progenitors may exist outside the marrow but do not normally differentiate in extramedullary sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of early hematopoietic cells, including the pluripotent stem cells and certain committed progenitor cells, have been demonstrated in the circulation of normal individuals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/22,74-76\">",
"     22,74-76",
"    </a>",
"    ]. HSC can also be found in the umbilical cord blood which is obtained from the placenta directly after delivery. Cord blood is enriched in stem cells compared with bone marrow or the peripheral circulation and can be used as a source for stem cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H63572418#H63572418\">",
"     \"Sources of hematopoietic stem cells\", section on 'Umbilical cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene expression profiling of primary CD34+ cells residing in the bone marrow and blood has revealed significant differences, with the marrow-derived cells cycling more rapidly, while the circulating CD34+ cells consist of a higher number of quiescent stem and progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. These differences, although of interest, could reflect the heterogeneity of the two populations, since stem cells able to reconstitute hematopoiesis comprise only a tiny subset of each population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Self-renewal versus differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two models have been proposed to explain the mechanisms that influence the choice of stem cells between self-renewal and differentiation (ie, lineage commitment). In one, self-renewal or differentiation is considered to occur in a random or stochastic manner, only dictated by a certain probability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/71,79\">",
"     71,79",
"    </a>",
"    ]. A contrasting model proposed that the hematopoietic microenvironment is inductive (HIM), based upon the observation that domains of a given lineage exist within single spleen colonies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/80\">",
"     80",
"    </a>",
"    ]. However, the preponderance of differentiating cells of one or other type within colonies appears to result from events that affect maturation rather than lineage commitment.",
"   </p>",
"   <p>",
"    There is now much evidence that supports the stochastic or random model for both lineage commitment and restriction of differentiation potential [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. In this model, combinations of nuclear transcription factors have been characterized that play a role in the specification of stem cells from mesenchymal cells and in early stem cell proliferation, while other unique sets of transcription factors appear to be activated, perhaps randomly. These transcription factors are essential for the development of the different cell lineages because they dictate the synthesis of lineage specific proteins such as cell surface growth factor receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. The possible role of extrinsic factors (such as leukopenia or anemia) in the regulation of stem cell levels is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     USES OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cell with the characteristics of a self-renewing multipotential stem cell has not been clearly defined in humans. However, the presence of stem cells capable of long term hematopoietic reconstitution (LTR-HSC) is inferred from the success of transplantation, using bone marrow, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    G-CSF mobilized blood, or umbilical cord blood as a source of stem cells in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major therapeutic uses for stem cells are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transplantation of allogeneic stem cells to reconstitute hematopoiesis in patients with either bone marrow failure or genetic disease.",
"     </li>",
"     <li>",
"      Transplantation of autologous or allogeneic stem cells to allow reconstitution of hematopoiesis in patients who might benefit from intensive radiochemotherapy for the treatment of malignant disease.",
"     </li>",
"     <li>",
"      Insertion of normal gene copies into genetically defective stem cells, which could then be transplanted and expressed long-term at sufficient levels to correct genetic disease.",
"     </li>",
"     <li>",
"      Insertion of additional copies of genes that would confer chemotherapy resistance to normal stem cells, thereby allowing dose escalation for the treatment of malignant disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much current research focuses on identification of the optimal donor and source (bone marrow or blood) of stem cells; stem cell purification to deplete contaminating tumor cells, reduce graft-versus host disease, and also optimize gene transfer; as well as ex vivo stem cell expansion to reduce malignant cell contamination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the amount of marrow required for successful engraftment.",
"   </p>",
"   <p>",
"    Under most circumstances the growth of LTR-HSC in the marrow appears to require a microenvironmental \"niche\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/1,90-92\">",
"     1,90-92",
"    </a>",
"    ]. Thus, isogeneic marrow infusions are not successful unless the recipient is irradiated or treated with sufficient doses of cytotoxic drugs to create an adequate number of \"niches.\" Experimentally, however, marrow ablation is unnecessary if very large numbers of stem cells are transplanted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MYSENCHYMAL STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult bone marrow and peripheral blood appear to contain a variable number of cells with the ability to differentiate into nonhematopoietic cells (eg, liver, kidney, heart, brain, endometrium, skeletal muscle, blood vessels, fingernails [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/94\">",
"     94",
"    </a>",
"    ]). Whether this ability can be used for potential clinical benefit is an area of intense research interest [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9897?source=see_link\">",
"     \"Overview of stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=see_link&amp;anchor=H11#H11\">",
"     \"Genetic and cellular therapy in heart failure and myocardial infarction\", section on 'Hematopoietic stem cell therapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Stem cells in other tissues'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H972088\">",
"    <span class=\"h1\">",
"     HUMAN EMBRYONIC STEM CELLS AND REPROGRAMMING OF SOMATIC CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past decade, remarkable advances have been made in the derivation of human embryonic stem cells (hESC) from the inner cell mass of blastocysts, based on earlier studies using murine ESC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/99\">",
"     99",
"    </a>",
"    ]. Co-culture of hESC with murine stromal cell lines derived from tissues such as bone marrow or yolk sac endothelial cells leads to the production of CD34+ hematopoietic progenitors that form erythroid, myeloid, and megakaryocytic colonies in semisolid media [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/100\">",
"     100",
"    </a>",
"    ]. Similarly, culture of hESC in fetal bovine serum and cytokines leads to formation of embryoid bodies that contain hematopoietic progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct reprogramming of differentiated somatic cells by gene transfer of a small number of transcription factors has emerged as a powerful method to create induced pluripotent stem (iPS) cells that are indistinguishable from embryonic stem cells. The original murine approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/102\">",
"     102",
"    </a>",
"    ] involved the delivery of only four genes, OCT4, SOX2, KLF4, and MYC to fibroblasts. This approach has been improved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/103\">",
"     103",
"    </a>",
"    ] and extended to human cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/104\">",
"     104",
"    </a>",
"    ]. Other investigators have demonstrated that human fibroblasts can be reprogrammed from patients with a variety of genetic defects, and cell sources include neonatal and adult fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/105,106\">",
"     105,106",
"    </a>",
"    ] as well as blood progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human ES or iPS cells may provide an optimal source of cells to study the developmental regulation of hematopoiesis. Furthermore, iPS cells derived from patients with genetic diseases may provide models for understanding the pathogenesis of the molecular defect, particularly in bone marrow failure diseases where hematopoietic stem cells are reduced. In addition, if the defect is evident in vitro, then such cells may provide a screen for compounds that can correct the phenotype. With respect to therapeutic applications, a practical goal of these studies is to derive HSC that can be used for transplantation, but this remains a major challenge. As discussed above, the in vivo SCID repopulating cell (SRC) assay in immunodeficient mice is the most valuable surrogate measure of long-term hematopoietic reconstitution, and results using both hESC and iPS cells show only low levels of engraftment. In the mouse, proof of principle for therapeutic use of reprogrammed cells has been obtained using somatic nuclear transfer to derive ES cells from",
"    <span class=\"nowrap\">",
"     Rag2-/-",
"    </span>",
"    immunodeficient mice, with subsequent repair of the defect by homologous recombination. Critically, introduction of the homeobox gene HoxB4 promoted the development of transplantable HSC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/108\">",
"     108",
"    </a>",
"    ]. iPS cells have been made from a sickle cell disease mouse, achieving a cure using a similar approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25129/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoiesis is sustained throughout the lifespan of an individual by a small number of pluripotent stem cells that slowly cycle from a larger quiescent pool. Stem cells have the capacity to self-renew and to commit to one or another of the hematopoietic lineages by a random process that induces a proliferation and differentiation program driven by sets of transcription factors.",
"   </p>",
"   <p>",
"    It appears likely that two types of extrinsic control can affect stem cell regulation. At one level is control by stromal cells, perhaps primarily on stem cell survival but also on their response to humoral factors. At a second level are the humoral growth factors, which appear to affect stem cells but probably have a greater affect on the amplification and differentiation of the committed maturing progenitors and precursors.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/1\">",
"      Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/2\">",
"      Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood 2008; 111:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/3\">",
"      Metcalf D. Hematopoietic cytokines. Blood 2008; 111:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/4\">",
"      Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005; 105:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/5\">",
"      Wilson A, Trumpp A. Bone marrow haematopoietic-stem-cell niches. Nature Rev Stem Cells Collection 2008; Supplement:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/6\">",
"      Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. Blood 2008; 111:3923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/7\">",
"      Xie Y, Yin T, Wiegraebe W, et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 2009; 457:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/8\">",
"      Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/9\">",
"      Majumdar MK, Thiede MA, Mosca JD, et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/10\">",
"      Jacobson LO, Marks EK, Gaston EO, et al. Role of the spleen in radiation injury. Proc Soc Exp Biol Med 1949; 70:7440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/11\">",
"      FORD CE, HAMERTON JL, BARNES DW, LOUTIT JF. Cytological identification of radiation-chimaeras. Nature 1956; 177:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/12\">",
"      TILL JE, McCULLOCH EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/13\">",
"      BECKER AJ, McCULLOCH EA, TILL JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963; 197:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/14\">",
"      Medvinsky AL, Samoylina NL, M&uuml;ller AM, Dzierzak EA. An early pre-liver intraembryonic source of CFU-S in the developing mouse. Nature 1993; 364:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/15\">",
"      Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 1996; 86:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/16\">",
"      Moore MA, Metcalf D. Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo. Br J Haematol 1970; 18:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/17\">",
"      Palis J, Yoder MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol 2001; 29:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/18\">",
"      Samokhvalov IM, Samokhvalova NI, Nishikawa S. Cell tracing shows the contribution of the yolk sac to adult haematopoiesis. Nature 2007; 446:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/19\">",
"      Morrison SJ, White PM, Zock C, Anderson DJ. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 1999; 96:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/20\">",
"      Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000; 97:14720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/21\">",
"      Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood 1999; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/22\">",
"      Fauser AA, Messner HA. Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood. Blood 1978; 52:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/23\">",
"      Fauser AA, Kanz L, Bross KJ, L&ouml;hr GW. T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 1985; 75:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/24\">",
"      Fauser AA, Messner HA. Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts. Blood 1979; 53:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/25\">",
"      Leary AG, Ogawa M, Strauss LC, Civin CI. Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. J Clin Invest 1984; 74:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/26\">",
"      Nakahata T, Ogawa M. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc Natl Acad Sci U S A 1982; 79:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/27\">",
"      Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977; 91:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/28\">",
"      Coulombel L, Kalousek DK, Eaves CJ, et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/29\">",
"      Greenberg HM, Newburger PE, Parker LM, et al. Human granulocytes generated in continuous bone marrow culture are physiologically normal. Blood 1981; 58:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/30\">",
"      Sutherland HJ, Lansdorp PM, Henkelman DH, et al. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A 1990; 87:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/31\">",
"      Breems DA, Blokland EA, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994; 8:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/32\">",
"      Bradley TR, Hodgson GS. Detection of primitive macrophage progenitor cells in mouse bone marrow. Blood 1979; 54:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/33\">",
"      McNiece IK, Stewart FM, Deacon DM, et al. Detection of a human CFC with a high proliferative potential. Blood 1989; 74:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/34\">",
"      Szilvassy SJ, Humphries RK, Lansdorp PM, et al. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc Natl Acad Sci U S A 1990; 87:8736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/35\">",
"      Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988; 242:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/36\">",
"      Terstappen LW, Huang S, Safford M, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991; 77:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/37\">",
"      Sutherland HJ, Eaves CJ, Eaves AC, et al. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989; 74:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/38\">",
"      Glimm H, Eisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. J Clin Invest 2001; 107:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/39\">",
"      Gunji Y, Nakamura M, Osawa H, et al. Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells. Blood 1993; 82:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/40\">",
"      Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/41\">",
"      Ratajczak MZ, Pletcher CH, Marlicz W, et al. CD34+, kit+, rhodamine123(low) phenotype identifies a marrow cell population highly enriched for human hematopoietic stem cells. Leukemia 1998; 12:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/42\">",
"      Ebihara Y, Wada M, Ueda T, et al. Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34+CD38- cells expressing Flk2/Flt3. Br J Haematol 2002; 119:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/43\">",
"      Fallon P, Gentry T, Balber AE, et al. Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol 2003; 122:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/44\">",
"      McKenzie JL, Takenaka K, Gan OI, et al. Low rhodamine 123 retention identifies long-term human hematopoietic stem cells within the Lin-CD34+CD38- population. Blood 2007; 109:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/45\">",
"      Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/46\">",
"      Kim M, Cooper DD, Hayes SF, Spangrude GJ. Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux. Blood 1998; 91:4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/47\">",
"      Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/48\">",
"      Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/49\">",
"      Nakauchi H. Hematopoietic stem cells: are they CD34-positive or CD34-negative? Nat Med 1998; 4:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/50\">",
"      Civin CI, Almeida-Porada G, Lee MJ, et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996; 88:4102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/51\">",
"      Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992; 89:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/52\">",
"      Srour EF, Zanjani ED, Cornetta K, et al. Persistence of human multilineage, self-renewing lymphohematopoietic stem cells in chimeric sheep. Blood 1993; 82:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/53\">",
"      Berenson RJ, Bensinger WI, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/54\">",
"      Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/55\">",
"      Zanjani ED, Almeida-Porada G, Livingston AG, et al. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol 1998; 26:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/56\">",
"      Bhatia M, Bonnet D, Murdoch B, et al. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 1998; 4:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/57\">",
"      Prabhash K, Khattry N, Bakshi A, et al. CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: potential predictor of early engraftment. Ann Oncol 2010; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/58\">",
"      Hellman S, Botnick LE, Hannon EC, Vigneulle RM. Proliferative capacity of murine hematopoietic stem cells. Proc Natl Acad Sci U S A 1978; 75:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/59\">",
"      Ma F, Wada M, Yoshino H, et al. Development of human lymphohematopoietic stem and progenitor cells defined by expression of CD34 and CD81. Blood 2001; 97:3755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/60\">",
"      Jones RJ, Wagner JE, Celano P, et al. Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells. Nature 1990; 347:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/61\">",
"      Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood 1995; 85:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/62\">",
"      Spangrude GJ, Johnson GR. Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci U S A 1990; 87:7433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/63\">",
"      Udomsakdi C, Eaves CJ, Sutherland HJ, Lansdorp PM. Separation of functionally distinct subpopulations of primitive human hematopoietic cells using rhodamine-123. Exp Hematol 1991; 19:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/64\">",
"      Kay HM. Hypothesis: How many cell-generations. Lancet 1965; 2:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/65\">",
"      Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A 1999; 96:3120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/66\">",
"      Van Zant G, de Haan G, Rich IN. Alternatives to stem cell renewal from a developmental viewpoint. Exp Hematol 1997; 25:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/67\">",
"      Harrison DE, Stone M, Astle CM. Effects of transplantation on the primitive immunohematopoietic stem cell. J Exp Med 1990; 172:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/68\">",
"      Morrison SJ, Wandycz AM, Akashi K, et al. The aging of hematopoietic stem cells. Nat Med 1996; 2:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/69\">",
"      Van Zant G, Holland BP, Eldridge PW, Chen JJ. Genotype-restricted growth and aging patterns in hematopoietic stem cell populations of allophenic mice. J Exp Med 1990; 171:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/70\">",
"      Nijnik A, Woodbine L, Marchetti C, et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 2007; 447:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/71\">",
"      TILL JE, MCCULLOCH EA, SIMINOVITCH L. A STOCHASTIC MODEL OF STEM CELL PROLIFERATION, BASED ON THE GROWTH OF SPLEEN COLONY-FORMING CELLS. Proc Natl Acad Sci U S A 1964; 51:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/72\">",
"      von Lindern M, Zauner W, Mellitzer G, et al. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 1999; 94:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/73\">",
"      Jacob J, Haug JS, Raptis S, Link DC. Specific signals generated by the cytoplasmic domain of the granulocyte colony-stimulating factor (G-CSF) receptor are not required for G-CSF-dependent granulocytic differentiation. Blood 1998; 92:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/74\">",
"      Calvo W, Fliedner TM, Herbst E, et al. Regeneration of blood-forming organs after autologous leukocyte transfusion in lethally irradiated dogs. II. Distribution and cellularity of the marrow in irradiated and transfused animals. Blood 1976; 47:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/75\">",
"      Barr RD, Whang-Peng J, Perry S. Hemopoietic stem cells in human peripheral blood. Science 1975; 190:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/76\">",
"      Clarke BJ, Housman D. Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci U S A 1977; 74:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/77\">",
"      Steidl U, Kronenwett R, Rohr UP, et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 2002; 99:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/78\">",
"      Terskikh AV, Miyamoto T, Chang C, et al. Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 2003; 102:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/79\">",
"      Marley SB, Lewis JL, Gordon MY. Progenitor cells divide symmetrically to generate new colony-forming cells and clonal heterogeneity. Br J Haematol 2003; 121:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/80\">",
"      Curry JL, Trentin JJ. Hemopoietic spleen colony studies. I. Growth and differentiation. Dev Biol 1967; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/81\">",
"      Gregory CJ, McCulloch EA, Till JE. Repressed growth of C57BL marrow in hybrid hosts reversed by antisera directed against non-H-2 alloantigens. Transplantation 1972; 13:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/82\">",
"      Suda T, Suda J, Ogawa M. Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc Natl Acad Sci U S A 1984; 81:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/83\">",
"      Lansdorp PM, Dragowska W. Maintenance of hematopoiesis in serum-free bone marrow cultures involves sequential recruitment of quiescent progenitors. Exp Hematol 1993; 21:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/84\">",
"      Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/85\">",
"      Shivdasani RA. Stem cell transcription factors. Hematol Oncol Clin North Am 1997; 11:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/86\">",
"      Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/87\">",
"      Metcalf D. Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation. Blood 1998; 92:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/88\">",
"      Enver T, Heyworth CM, Dexter TM. Do stem cells play dice? Blood 1998; 92:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/89\">",
"      Chu P, Lutzko C, Stewart AK, Dub&eacute; ID. Retrovirus-mediated gene transfer into human hematopoietic stem cells. J Mol Med (Berl) 1998; 76:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/90\">",
"      Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/91\">",
"      Schofield R. The pluripotent stem cell. Clin Haematol 1979; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/92\">",
"      Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/93\">",
"      Stewart FM, Crittenden RB, Lowry PA, et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 1993; 81:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/94\">",
"      Imanishi D, Miyazaki Y, Yamasaki R, et al. Donor-derived DNA in fingernails among recipients of allogeneic hematopoietic stem-cell transplants. Blood 2007; 110:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/95\">",
"      Dezawa M, Ishikawa H, Itokazu Y, et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005; 309:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/96\">",
"      Porat Y, Porozov S, Belkin D, et al. Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages. Br J Haematol 2006; 135:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/97\">",
"      Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 2009; 114:3513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/98\">",
"      Rivi&egrave;re I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood 2012; 119:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/99\">",
"      Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/100\">",
"      Kaufman DS, Hanson ET, Lewis RL, et al. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2001; 98:10716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/101\">",
"      Chadwick K, Wang L, Li L, et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 2003; 102:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/102\">",
"      Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/103\">",
"      Eminli S, Foudi A, Stadtfeld M, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009; 41:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/104\">",
"      Hanley J, Rastegarlari G, Nathwani AC. An introduction to induced pluripotent stem cells. Br J Haematol 2010; 151:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/105\">",
"      Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/106\">",
"      Park IH, Lerou PH, Zhao R, et al. Generation of human-induced pluripotent stem cells. Nat Protoc 2008; 3:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/107\">",
"      Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood 2009; 113:5476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/108\">",
"      Rideout WM 3rd, Hochedlinger K, Kyba M, et al. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 2002; 109:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25129/abstract/109\">",
"      Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3536 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25129=[""].join("\n");
var outline_f24_34_25129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BONE MARROW ANATOMY AND MICROENVIRONMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMATOPOIETIC STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stem cells in other tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Identification of stem and progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - In vitro assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cell surface antigenic markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STEM CELL HETEROGENEITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STEM CELL REGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Self-renewal versus differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      USES OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MYSENCHYMAL STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H972088\">",
"      HUMAN EMBRYONIC STEM CELLS AND REPROGRAMMING OF SOMATIC CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3536|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3536|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/33/1567\" title=\"figure 1\">",
"      Stem cell properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/4/17483\" title=\"table 1\">",
"      Growth factors and stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18617?source=related_link\">",
"      Genetic and cellular therapy in heart failure and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9897?source=related_link\">",
"      Overview of stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=related_link\">",
"      Regulation of myelopoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25130="Preparative regimens for hematopoietic cell transplantation";
var content_f24_34_25130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preparative regimens for hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25130/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25130/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/34/25130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/34/25130/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/34/25130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant procedure. The purpose of the preparative regimen is twofold:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To provide adequate immunosuppression to prevent rejection of the transplanted graft",
"     </li>",
"     <li>",
"      To eradicate the disease for which the transplant is being performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These goals have traditionally been achieved by delivering maximally tolerated doses of multiple chemotherapeutic agents with non-overlapping toxicities, with or without radiation. Several novel approaches have been evaluated in an attempt to minimize toxicity. As an example, nonmyeloablative preparative regimens have been developed to treat older patients or those with concurrent medical conditions. Another alternative is targeted therapy in the form of radiolabeled monoclonal antibodies.",
"   </p>",
"   <p>",
"    The toxicity associated with preparative regimens and an overview of the more common regimens currently in use will be presented here. The preferred preparative regimen for specific diseases and the approaches to prevention of the other major complications of hematopoietic cell transplantation (eg, graft-versus-host disease) are discussed separately. There are also occasional settings in which transplantation can be performed without any preparation, primarily in children with severe combined immunodeficiency who lack T-cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREPARATIVE REGIMEN INTENSITY DEFINED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparative regimens for HCT have been termed myeloablative, reduced intensity, and nonmyeloablative. While full agreement has not been achieved, generally accepted definitions of these three types of regimens are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Myeloablative regimens",
"      </strong>",
"      &mdash; A myeloablative (MA) regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and results in profound pancytopenia within one to three weeks from the time of administration. The resulting pancytopenia is long-lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells. Examples include total body irradiation &ge;5 Gy in a single dose or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      &gt;8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myeloablative preparative regimens'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Nonmyeloablative regimens",
"      </strong>",
"      &mdash; A nonmyeloablative (NMA) regimen is one that will cause minimal cytopenia (but significant lymphopenia) by itself and does not require stem cell support. Examples include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with or without antithymocyte globulin or total body irradiation &le;2 Gy with or without a purine analog. However, the transplant, when given in this setting usually becomes myeloablative, because the engrafting donor T-cells will eventually eliminate host hematopoietic cells, allowing the establishment of donor hematopoiesis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonmyeloablative and reduced intensity preparative regimens'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Reduced intensity regimens",
"      </strong>",
"      &mdash; Reduced intensity regimens (RIC) are an intermediate category of regimens that do not fit the definition of myeloablative or nonmyeloablative. Such regimens cause cytopenias, which may be prolonged and result in significant morbidity and mortality, and require hematopoietic stem cell support. Regimens generally considered as reduced intensity include &le;9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , or &le;140",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMMON TOXICITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the preparative regimens discussed below have side effects that can be life-threatening. In addition to myelotoxicity, other common toxicities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucositis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"       \"Oral toxicity associated with chemotherapy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nausea and vomiting (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alopecia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=see_link\">",
"       \"Chemotherapy-induced alopecia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diarrhea (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link\">",
"       \"Enterotoxicity of chemotherapeutic agents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rash",
"     </li>",
"     <li>",
"      Peripheral neuropathies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link\">",
"       \"Neurologic complications of non-platinum cancer chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link\">",
"       \"Neurologic complications of platinum-based chemotherapy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infertility, which can be devastating to young patients, is almost universal when using myeloablative regimens. This can be addressed with sperm cryopreservation for male patients, assuming they have adequate sperm number and function. Oocyte cryopreservation in female patients can also be attempted, with generally less favorable results.",
"   </p>",
"   <p>",
"    Pulmonary and hepatic toxicity are also relatively common. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , which is a component of many preparative regimens, can produce both interstitial lung disease and hepatic venoocclusive disease or sinusoidal obstructive syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As a result, it is imperative that patients be screened prior to initiating the preparative regimen to avoid unnecessary risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Total body irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term complications following total body irradiation (TBI) used as part of a HCT preparative regimen are common. In one study of 186 adults surviving at least one year following TBI and HCT, who were followed for a median time of four years (range one to 11 years), the most commonly seen complications included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic alterations in pulmonary function &mdash; 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cataracts &mdash; 15 percent; surgery was necessary in 57 percent",
"     </li>",
"     <li>",
"      Sicca syndrome &mdash; 13 percent",
"     </li>",
"     <li>",
"      Hypothyroidism &mdash; 6.5 percent; one-half required medical treatment",
"     </li>",
"     <li>",
"      Thyroiditis &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MYELOABLATIVE PREPARATIVE REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of myeloablative regimens have been employed at centers throughout the world. They have generally used total body irradiation with or without chemotherapy, or chemotherapy alone. These regimens were developed by escalating the dose of either radiation or a particular drug to the maximally tolerated dose. Drugs with non-overlapping toxicities were employed in an effort to avoid synergistic injury to a particular organ (",
"    <a class=\"graphic graphic_table graphicRef54359 \" href=\"UTD.htm?5/63/6139\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Preparative regimen intensity defined'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In all instances, hematopoietic toxicity was ignored and, since this system is the most sensitive to the effects of radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytotoxic chemotherapy, all regimens were associated with a high degree of myelotoxicity. The extent to which any particular regimen is in fact myeloablative is very hard to know with certainty.",
"   </p>",
"   <p>",
"    There are only a few randomized trials directly comparing the efficacy of one myeloablative preparative regimen to another, As a result, it is difficult to make direct statements about the suitability of a given preparative regimen in a particular disease setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiation-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body irradiation (TBI) has been the mainstay of preparative regimens since the inception of HCT, based upon early studies in the dog and other animal models. Initial preparative regimens included TBI administered as a single dose using opposing Cobalt-60 sources [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/12\">",
"     12",
"    </a>",
"    ]. At present, TBI-based regimens typically fractionate the radiation and administer the total dose over several days, typically four, which helps decrease toxicity and increase tolerability (",
"    <a class=\"graphic graphic_table graphicRef60441 \" href=\"UTD.htm?10/2/10284\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/13\">",
"     13",
"    </a>",
"    ]. Partial lung shielding is included in an effort to reduce the potential for irreversible lung injury.",
"   </p>",
"   <p>",
"    In the initial regimens, TBI was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (Cy) and this",
"    <span class=\"nowrap\">",
"     TBI/Cy",
"    </span>",
"    combination is still widely used. Cyclophosphamide is usually given at a dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of adjusted ideal body weight on each of two successive days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maximally tolerated dose of TBI is approximately 15 Gy. Higher doses produce excessive nonhematologic toxicity, primarily to the lungs, but also to other organs including the heart. Two randomized trials evaluated the efficacy of different doses of TBI (12 and 16 Gy) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , prior to allogeneic HCT in patients with acute myeloid leukemia in first remission and chronic myeloid leukemia in the chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Decreased relapse rates were observed with the higher TBI dose (eg, 12 versus 35 percent at three years in patients with acute myeloid leukemia), but overall survival was similar due primarily to increased transplant-related mortality at the higher doses (eg, 32 versus 12 percent at three years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/17\">",
"     17",
"    </a>",
"    ]. This observation has provided one of the major rationales for developing radiolabeled monoclonal antibodies as part of the preparative regimen (see below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    (VP16) has also been given with fractionated TBI at a maximally tolerated dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/19\">",
"     19",
"    </a>",
"    ], with excellent results having been obtained in large numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, VP 16 has been combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and TBI",
"    <span class=\"nowrap\">",
"     (TBI/CY/VP16)",
"    </span>",
"    in both the autologous and allogeneic setting, in an attempt to reduce relapse rates in patients with high risk or advanced stage hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (cytosine arabinoside, usually at a dose of 3 g every 12 hours for six days) also has been given with TBI, with and without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , in patients with acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The rationale for this approach is to reduce the likelihood of relapse via the antileukemic activity of cytarabine. However, the possibility superiority of using cytarabine rather than cyclophosphamide remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major limitations of fractionated TBI include mucositis, lung toxicity, infertility, and the relatively sophisticated instrumentation required to effectively administer this treatment. However, keratinocyte growth factor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    ) has been successful in reducing the risk of mucositis following radiation-containing regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractionated TBI has been relatively difficult to standardize in multi-institutional trials, due to differences in dose rates, shielding, and center-specific techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chemotherapy without radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of regimens have been developed in which TBI is replaced with additional chemotherapeutic agents (",
"    <a class=\"graphic graphic_table graphicRef50359 \" href=\"UTD.htm?25/26/26029\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/28\">",
"     28",
"    </a>",
"    ]. These approaches have primarily been developed for autologous transplantation, but they have also been used widely in the allogeneic setting. The primary advantage of regimens that lack TBI is reduced toxicity. In addition, the cost is lower, the regimen is easier to administer and schedule, and radiation can still be given to sites of prior disease following the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug combinations have been selected based upon the biologic activity of the particular drug, the ability to escalate the dose of the drug, and non-overlapping toxicities when delivering the drugs at maximally tolerated dosages. The most widely used non-radiation-containing regimen is the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <span class=\"nowrap\">",
"     (Bu/Cy)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/6,30-36\">",
"     6,30-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    appears to be influenced by the pharmacokinetics in each individual. In one series of 45 patients with chronic myeloid leukemia, the steady state serum drug concentrations achieved after the oral administration of busulfan varied widely (642 to 1749",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    following the standard dose of 16",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients who achieved drug levels below the median had an increased rate of relapse compared with those with values above the median (32 versus zero percent). An intravenous formulation of busulfan reduces this variability and is in routine clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/38\">",
"     38",
"    </a>",
"    ]. The administration of adjusted dose IV busulfan with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has resulted in excellent outcomes with improved tolerability for patients with chronic myeloid leukemia and an overall survival at three years of 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other non-radiation-containing regimens that have been successful include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    in patients with acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/18,40,41\">",
"     18,40,41",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (BCNU), and etoposide, which is widely used in patients with Hodgkin and non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Different doses and schedules of these drugs have been employed at various transplant centers, making it difficult to compare results with this regimen from one study to the next.",
"   </p>",
"   <p>",
"    BCNU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , cytosine arabinoside and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (BEAM) is also a widely used preparative regimen for both autologous and allogeneic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant problem with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    -containing regimens has been the relatively high incidence of pulmonary toxicity, particularly in patients who have received prior radiotherapy to the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This condition typically responds to corticosteroids (approximate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    especially in early disease. In an attempt to minimize this risk,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    (CCNU) has been used in place of carmustine in patients at high risk for lung toxicity, however, it is unclear if this reduces the risk of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach to minimizing lung toxicity is the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    , followed by autologous peripheral blood progenitor cells in patients with aggressive or relapsed lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/49\">",
"     49",
"    </a>",
"    ]. Among the 40 patients treated with this regimen, interstitial pneumonitis developed in only one patient who had received prior lung radiotherapy.",
"   </p>",
"   <p>",
"    The preparative regimen also may vary with the nature of the underlying disease. Among patients with aplastic anemia, for example, it is desirable to increase the degree of immunosuppression (to prevent rejection of the graft) while avoiding excessive myelotoxicity. This has been successfully achieved with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and antithymocyte globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comparison of radiation with chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to compare the relative efficacy of the large number of different preparative regimens that have been developed, since there are few direct comparisons in randomized clinical trials. In addition, it is likely that patient selection has a large impact on the results obtained, making it difficult to assess the impact of any given preparative regimen from the large number of phase II trials reported in the literature. An instructive example was reported in a retrospective cohort study which compared a radiation-containing preparative regimen",
"    <span class=\"nowrap\">",
"     (TBI/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"     )",
"    </span>",
"    with a chemotherapy-only regimen (BEAM) in patients with non-Hodgkin lymphoma undergoing autologous peripheral blood stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/51\">",
"     51",
"    </a>",
"    ]. The TBI-containing regimen resulted in relapse-free and overall survivals similar to that after BEAM. Further analysis indicated that transplantation before the year 2000, rather than the conditioning regimen, was a more important predictive factor for long-term outcome.",
"   </p>",
"   <p>",
"    Despite these difficulties, a number of retrospective and randomized trials, including one meta-analysis, have compared",
"    <span class=\"nowrap\">",
"     Bu/Cy",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     TBI/Cy",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/6,10,31,52\">",
"     6,10,31,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Bone Marrow Transplant Registry retrospectively compared outcomes following allogeneic HCT in 381 HLA-matched sibling transplants receiving",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      with 200 transplants using",
"      <span class=\"nowrap\">",
"       TBI/Cy",
"      </span>",
"      for acute myeloid leukemia in first remission [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/52\">",
"       52",
"      </a>",
"      ]. The incidence of hepatic sinusoidal obstructive syndrome (SOS, previously called hepatic veno-occlusive disease (VOD)), was higher with",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      than with",
"      <span class=\"nowrap\">",
"       TBI/Cy",
"      </span>",
"      (13 versus 6 percent, p = 0.009) and the relapse risk was higher with",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      (relative risk 1.7, 95 percent confidence interval: 1.05 to 2.81). Nevertheless, there were no differences in treatment-related mortality, risk for acute or chronic graft-versus-host disease, leukemia-free survival, or overall survival between the two treatments.",
"     </li>",
"     <li>",
"      A meta-analysis of five prospective randomized studies comparing",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      with",
"      <span class=\"nowrap\">",
"       TBI/Cy",
"      </span>",
"      came to similar conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/10\">",
"       10",
"      </a>",
"      ], with an increased risk of hepatic SOS in the",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      group (odds ratio 2.5, 95% CI: 1.2-5.2) but no significant differences in acute or chronic GVHD, interstitial pneumonitis, disease-free survival, or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies did not include dose adjustment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    based upon pharmacokinetics, which may have an impact on regimen-related complications, such as hepatic SOS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\", section on 'Conditioning therapy and drug toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MULTIPLE CYCLES OF HIGH DOSE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major advance in the field of transplantation has been the introduction of mobilized peripheral blood progenitor cells (PBPCs) as the source of hematopoietic stem cells. The rapidity of engraftment correlates with the dose of CD34+ cells, such that more than 2 x 10(6) CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    are required for rapid neutrophil recovery, while more than 5 x",
"    <span class=\"nowrap\">",
"     10(6)/kg",
"    </span>",
"    can hasten platelet recovery and may be preferred in patients with prolonged pretransplant chemotherapy exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many patients, collection of stem cell doses far exceeding these thresholds can be readily achieved. This permits an approach consisting of multiple cycles of high dose chemotherapy followed by the infusion of PBPCs after each cycle, in an attempt to increase the intensity of anticancer therapy beyond that achievable with a standard autologous transplant. Each cycle is at or near myeloablative levels of chemotherapy, followed by rescue with previously collected PBPCs.",
"   </p>",
"   <p>",
"    A variety of diseases have been treated in this fashion in pilot studies, including metastatic breast cancer, Hodgkin's disease, and non-Hodgkin lymphomas; impressive response rates have been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Many of these regimens have been administered on an outpatient basis with pulmonary and gastrointestinal toxicities being the major limiting factors. At present, there is little evidence that this approach increases the long-term disease free survival rate over that achieved with a standard transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A trial involving several cooperative groups is evaluating the impact of double versus single autologous transplantation for patients with high-risk Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    An exception is the use of tandem autologous transplantation for the treatment of multiple myeloma. In this setting tandem transplantation with two rounds of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    was shown to be more effective than a single transplant, especially in those patients who did not achieve a complete remission following the first transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RADIOLABELED MONOCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the maximally tolerated dose of TBI is approximately 15 Gy. Randomized trials comparing 12 and 16 Gy found that the higher dose was associated with a lower relapse rate (eg, 12 versus 35 percent at three years in patients with acute myeloid leukemia), but no improvement in overall survival due to a higher rate of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These observations suggest that improvements in disease-free survival might be attained if the radiation dose could be increased without excessive toxicity.",
"   </p>",
"   <p>",
"    One approach to achieving this goal has been the administration of monoclonal antibodies radiolabeled with high energy emitting radioisotope. This would permit targeting of the radiation dose to the tumor cells and marrow with potential reduction in dose to other organs, such as the liver, lungs and kidneys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675564#H19675564\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Radioimmunoconjugates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anti-CD45 antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;One such monoclonal antibody is directed against CD45, which is highly expressed on hematopoietic cells, thereby allowing targeting to the marrow space [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In one report, 34 patients with advanced acute leukemia or myelodysplastic syndrome were treated with an iodine-131 conjugated CD45 monoclonal antibody, which resulted in an estimated marrow dose of 40 to 300 Gy, followed by conventional doses of fractionated TBI (12",
"    <span class=\"nowrap\">",
"     Gy)/Cy",
"    </span>",
"    and autologous or HLA-matched related allogeneic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/61\">",
"     61",
"    </a>",
"    ]. Toxicity was no greater than expected and response rates were excellent. Among 25 treated patients with acute myeloid leukemia or myelodysplastic syndrome, seven are alive and disease-free at a median of 65 months after transplantation.",
"   </p>",
"   <p>",
"    Addition of this monoclonal antibody to patients being treated with the",
"    <span class=\"nowrap\">",
"     Bu/Cy",
"    </span>",
"    regimen, compared to registry data using",
"    <span class=\"nowrap\">",
"     Bu/Cy",
"    </span>",
"    alone, was associated with a more favorable outcome for patients receiving the radiolabeled antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H944694131\">",
"    <span class=\"h2\">",
"     Anti-CD66 antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD66 is highly expressed on normal myelopoietic cells from the promyelocyte to the mature granulocyte. In one report, 30 pediatric and adolescent patients undergoing allogeneic HCT for malignant (16 patients) or nonmalignant (14 patients) disorders underwent conditioning with yttrium-90 conjugated CD66 monoclonal antibody in combination with a reduced intensity (RIC) or myeloablative conditioning regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/63\">",
"     63",
"    </a>",
"    ]. The combination of antibody plus RIC resulted in consistent myeloablation and stable complete donor chimerisms in the setting of nonmalignant hematologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anti-CD20 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     Tositumomab",
"    </a>",
"    (Bexxar), an Iodine-131 conjugated anti-CD20 antibody, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    (Zevalin), an Yttrium-90 conjugated anti-CD20 antibody have been added to standard preparative regiments in the autologous setting for the treatment of patients with B-cell NHL, with encouraging preliminary results and tolerable toxicity profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. A randomized trial comparing Bexxar-BEAM with BEAM has been conducted by the Bone Marrow Transplantation Clinical Trials Network (BMT-CTN). Patient accrual has been completed but results have not yet been released.",
"   </p>",
"   <p>",
"    A variety of other monoclonal antibodies and radioisotopes are likely to be tested in the future. This approach raises the possibility of directing the preparative regimen to sites of disease, thereby sparing normal tissues. One concern is that high doses of radioactivity delivered to the marrow space may injure or kill stromal cells. In addition, the delivery of such high doses of some of the radioisotopes requires sophisticated expertise, equipment, and shielding of the patient to avoid risk to health care workers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONMYELOABLATIVE AND REDUCED INTENSITY PREPARATIVE REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General principles and examples",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with leukemia treated with allogeneic HCT, an important contributing factor is a graft-versus-tumor (GVT) effect mediated by donor immunocompetent cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/67\">",
"     67",
"    </a>",
"    ]. The importance of GVT is illustrated by the different outcomes with grafts from identical twin and nonidentical donors. Patients who have an identical twin donor do not develop either GVHD or GVT, and are therefore at higher risk of relapse of the underlying malignant disease than similar patients transplanted with HLA-matched but nonidentical sibling donors (who develop both GVHD and GVT).",
"   </p>",
"   <p>",
"    These relationships were illustrated in a review from 163 transplant centers that compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for various forms of acute or chronic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/68\">",
"     68",
"    </a>",
"    ]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than in the allogeneic transplants in acute myelocytic leukemia (52 versus 16 percent) and chronic myelocytic leukemia (40 versus 7 percent). Survival was similar with the two types of transplants because the increased incidence of leukemia relapse with identical twin transplants was counterbalanced by less treatment-related mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The GVT effect requires the engraftment of donor type immunocompetent cells, which does not necessarily require a high dose myeloablative preparative regimen (",
"    <a class=\"graphic graphic_figure graphicRef75962 \" href=\"UTD.htm?13/23/13694\">",
"     figure 1",
"    </a>",
"    ). As a result, the possibility of achieving donor-specific engraftment using nonmyeloablative or reduced intensity regimens (\"minitransplants\", although this term is a poor choice for describing a potentially complicated procedure) has been extensively explored [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/3,69-73\">",
"     3,69-73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Preparative regimen intensity defined'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This approach, which relies more on donor cellular immune effects and less on the cytotoxic effects of the preparative regimen to control the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/67,74,75\">",
"     67,74,75",
"    </a>",
"    ], permits transplantation in older, as well as high-risk, heavily pretreated patients of any age, with an attendant decrease in regimen-related toxicity and treatment-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/76-84\">",
"     76-84",
"    </a>",
"    ]. A number of salient observations are the underpinnings of these nonmyeloablative approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In many instances, cancer cells cannot be eradicated entirely by high dose chemotherapy alone (eg, multiple myeloma), or patients with these disorders are too ill because of age",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      co-morbidities to tolerate myeloablative chemotherapy followed by transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/77,85,86\">",
"       77,85,86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link\">",
"       \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many of the observed long-term tumor responses have been brought about by immunologic antitumor effects (ie, the GVT effect) generated by the allograft (eg, donor lymphocyte infusion in CML relapsing after allogeneic HCT) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H3#H3\">",
"       \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'Allogeneic HCT'",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/67,87\">",
"       67,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Not all diseases are equally susceptible to GVT effects. Follicular non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, and chronic myeloid leukemia appear particularly responsive, whereas acute lymphoblastic leukemia and Hodgkin lymphoma are relatively resistant. The biological explanation for these observations remains elusive.",
"      <br/>",
"      <br/>",
"      As an example, in one analysis of 834 patients, the overall relapse rate per patient year was 0.36. Patients with chronic lymphocytic leukemia, multiple myeloma in remission, low grade or mantle cell lymphoma, and high grade non-Hodgkin lymphoma had the lowest rates (0-0.24), whereas those with advanced myeloid and lymphoid malignancies had rates of more than 0.52 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For many genetic disorders, a state of mixed donor-host chimerism is sufficient to relieve the patient of disease-related manifestations (eg, beta thalassemia major). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=see_link&amp;anchor=H16#H16\">",
"       \"Specific issues related to hematopoietic cell transplantation in beta thalassemia\", section on 'Mixed chimeric state'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      -based conditioning regimens have been widely studied in the setting on non-myeloablative allogeneic transplantation. Fludarabine has been combined with a variety of other agents including busulphan,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , and low dose irradiation. All of these studies have shown promise and are being used by different centers. To date, there have not been any randomized trials comparing one approach to another. All have merit and appear to be reasonably well tolerated in older individuals and in patients with significant co-morbid medical conditions, including patients who have undergone prior autologous transplantation.",
"     </li>",
"     <li>",
"      A number of studies have been performed to determine whether non-myeloablative allogeneic transplantation might be effective in patients with solid tumors. Patients with metastatic renal cell carcinoma and other solid tumors have shown clinical responses and evidence for a graft-versus-tumor effect after use of nonmyeloablative allogeneic HCT with or without subsequent donor lymphocyte infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/67,74,89,90\">",
"       67,74,89,90",
"      </a>",
"      ]. Unfortunately, only a minority of patients appears to respond to this approach and non-myeloablative transplantation for solid tumors has generally not been very effective. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H30#H30\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Nonmyeloablative allogeneic hematopoietic cell transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A novel approach, based upon murine studies that show a marked resistance to GVHD induction, has been to combine total lymphoid irradiation (TLI) with anti-thymocyte globulin (ATG). In this approach, TLI and ATG appear to alter the host immune profile to favor regulatory natural killer T (NKT) cells that suppress GVHD but retain graft antitumor activity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/91\">",
"       91",
"      </a>",
"      ]. Initial studies of this approach appeared promising, with an apparent reduction in acute GVHD risk with retention of GVT effects [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/92\">",
"       92",
"      </a>",
"      ]. Follow-up of this study in 111 patients demonstrated a low risk of acute GVHD and low transplant-related mortality at one year of 3 and 4 percent for recipients of related and unrelated donors, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the light of reduced intensity of conditioning regimens, and with the induction of partial chimerism, donor leukocyte infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/94\">",
"     94",
"    </a>",
"    ] or other immunotherapeutic interventions could be applied in an effort to balance the interactions between the following competing issues (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/92,95-103\">",
"     92,95-103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maximizing the graft-versus-tumor effect (",
"      <a class=\"graphic graphic_figure graphicRef75962 \" href=\"UTD.htm?13/23/13694\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Minimizing acute and chronic graft versus host disease (GVHD)",
"     </li>",
"     <li>",
"      Minimizing graft rejection",
"     </li>",
"     <li>",
"      Minimizing opportunistic infections (eg, CMV infection) through rapid immune reconstitution [",
"      <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/104\">",
"       104",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach relies heavily on the serial assessment of chimerism, using techniques such as fluorescence in situ hybridization (FISH) or analysis of a variable number of tandem repeats (VNTR) between donor and recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/105-109\">",
"     105-109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538631#H15538631\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Fluorescence in situ hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clearly, much needs to be done to determine the relative role of this transplant approach, including such variables as the age and overall comorbidity status of the recipient, presence or absence of complete or partial remission at the time of HCT and clinical aggressiveness of the underlying disorder, the degree of HLA matching of the donor, and the agents and doses used in the reduced intensity conditioning regimens and GVHD prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/88,110-114\">",
"     88,110-114",
"    </a>",
"    ]. However, these approaches have been tolerated reasonably well even in patients who are elderly and have significant medical co-morbidities, allowing for many more patients to be treated with transplantation. This is important because many of the diseases for which allogeneic HCT has been successful typically occur in patients in their fifth to seventh decades of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antibody-based minimal intensity conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients, such as those with severe organ toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     DNA/telomere",
"    </span>",
"    repair defects may be unable to tolerate myeloablative or even nonmyeloablative regimens and may be candidates for minimal intensity conditioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link&amp;anchor=H10#H10\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\", section on 'Complications after HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This concept was tested in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study in 16 high-risk patients who underwent allogeneic HCT for primary combined immunodeficiency. The conditioning regimen included the use of two rat anti-CD45 antibodies, an anti-CD52 antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/115\">",
"     115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rates of clinically significant acute and chronic GVHD were 36 and 31 percent, respectively. No grade 4 toxicities were seen.",
"     </li>",
"     <li>",
"      Fifteen of the 16 patients engrafted, of whom 11 achieved full or high-level mixed chimerism in both lymphoid and myeloid lineages.",
"     </li>",
"     <li>",
"      At a median follow-up of 40 months post-HCT, 13 of the 16 patients (81 percent) were alive and cured of their underlying disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar reduced intensity conditioning regimen (RIT), involving the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (FMC), was tested in 157 consecutive patients undergoing allogeneic HCT to determine whether the use of T-cell depletion with alemtuzumab might reduce the adverse effect of an HLA mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/116\">",
"     116",
"    </a>",
"    ]. HCT donors in this study were 107 unrelated donors who were",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    HLA-matched (MUD) and 50 unrelated donors who were matched at 6 to 9 of the 10 HLA loci (MMUD). Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft failure rates were similar between the two groups (8 versus 3 percent), although rejection was more frequent in MMUDs (8 versus 0 percent).",
"     </li>",
"     <li>",
"      There were no significant differences between donors in the incidences of grades II-IV acute GVHD (20 versus 22 percent), chronic extensive GVHD at 3 years (23 versus 24 percent), or treatment-related mortality at one year (27 percent for both).",
"     </li>",
"     <li>",
"      Three-year overall survivals were similar (53 versus 49 percent) between the two donor groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study evaluated different",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    doses (20 mg, 30 mg, 40 mg, and 60 mg) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    as the conditioning regimen of 106 patients undergoing an HLA-identical sibling HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/34/25130/abstract/117\">",
"     117",
"    </a>",
"    ]. When compared with higher doses of alemtuzumab, the 20 mg dose was associated with a greater risk of severe GVHD. In contrast, when compared with higher doses, the 30 mg dose had similar rates of severe GVHD and other clinical endpoints, but better lymphocyte recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103575063\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant (HCT) procedure. The purpose of the preparative regimen is twofold:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      To provide adequate immunosuppression to prevent rejection of the transplanted graft",
"     </li>",
"     <li>",
"      To treat the disease for which the transplant is being performed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preparative regimens for HCT have been termed myeloablative, reduced intensity, and nonmyeloablative. While full agreement has not been achieved, generally accepted definitions of these three types are as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Myeloablative regimens",
"      </strong>",
"      &mdash; A myeloablative regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and produce profound pancytopenia. The resulting pancytopenia is long-lasting, likely irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells. Examples include total body irradiation &ge;5 Gy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      &gt;8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myeloablative preparative regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Nonmyeloablative regimens",
"      </strong>",
"      &mdash; A nonmyeloablative regimen is one that will cause minimal cytopenia (but significant lymphopenia) by itself and does not require stem cell support. Examples include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with or without antithymocyte globulin or total body irradiation &le;2 Gy with or without a purine analog. However, the transplant, when given in this setting usually results in full donor engraftment because the engrafting donor T-cells will eventually eliminate host hematopoietic cells, allowing the establishment of donor hematopoiesis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonmyeloablative and reduced intensity preparative regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Reduced intensity regimens",
"      </strong>",
"      &mdash; Reduced intensity regimens are an intermediate category of regimens that do not fit the definition of myeloablative or nonmyeloablative. Such regimens cause cytopenia, which may be prolonged and result in significant morbidity and mortality, and require stem cell support. Regimens generally considered as reduced intensity include &le;9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , or &le;140",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients, such as those with severe organ toxicity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       DNA/telomere",
"      </span>",
"      repair defects, may be unable to tolerate myeloablative or even nonmyeloablative regimens and may be candidates for minimal intensity conditioning. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibody-based minimal intensity conditioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are only a few randomized trials directly comparing the efficacy of one myeloablative preparative regimen with another, As a result, it is difficult to make direct statements about the suitability of a given preparative regimen in a particular disease setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myeloablative preparative regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All of the preparative regimens have short and long term side effects in addition to myelotoxicity. Other common toxicities include mucositis, nausea and vomiting, alopecia, diarrhea, rash, peripheral neuropathy, infertility, interstitial lung disease, and sinusoidal obstructive syndrome. Long-term complications following total body irradiation also include asymptomatic alterations in pulmonary function, cataracts, sicca syndrome, and thyroid dysfunction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Common toxicities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/1\">",
"      Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/2\">",
"      Khouri IF, Keating M, K&ouml;rbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/3\">",
"      Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/4\">",
"      Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/5\">",
"      Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/6\">",
"      Ringd&eacute;n O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/7\">",
"      Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol 1999; 16:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/8\">",
"      Thomas O, Mah&eacute; M, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001; 49:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/9\">",
"      Gopal R, Ha CS, Tucker SL, et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001; 92:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/10\">",
"      Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/11\">",
"      Soci&eacute; G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98:3569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/12\">",
"      Buckner CD, Epstein RB, Rudolph RH, et al. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970; 35:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/13\">",
"      Shank B, Chu FC, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/14\">",
"      Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/15\">",
"      Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys 1982; 8:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/16\">",
"      Santos GW, Sensenbrenner LL, Burke PJ, et al. Allogeneic marrow grafts in man using cyclophosphamide. Transplant Proc 1974; 6:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/17\">",
"      Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/18\">",
"      Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/19\">",
"      Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/20\">",
"      Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993; 82:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/21\">",
"      Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994; 84:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/22\">",
"      Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/23\">",
"      Horning SJ, Negrin RS, Chao JC, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/24\">",
"      Weaver CH, Petersen FB, Appelbaum FR, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/25\">",
"      Riddell S, Appelbaum FR, Buckner CD, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988; 6:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/26\">",
"      Jillella AP, Doria R, Khan K, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant 1999; 23:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/27\">",
"      Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/28\">",
"      Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/29\">",
"      Shah AB, Hartsell WF, Ghalie R, Kaizer H. Patterns of failure following bone marrow transplantation for metastatic breast cancer: the role of consolidative local therapy. Int J Radiat Oncol Biol Phys 1995; 32:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/30\">",
"      Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/31\">",
"      Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/32\">",
"      O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/33\">",
"      Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/34\">",
"      Copelan EA, Biggs JC, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/35\">",
"      Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 1998; 850:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/36\">",
"      Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013; 31:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/37\">",
"      Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89:3055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/38\">",
"      Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/39\">",
"      Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/40\">",
"      Chao NJ, Stein AS, Long GD, et al. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993; 81:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/41\">",
"      Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/42\">",
"      Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/43\">",
"      Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/44\">",
"      Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/45\">",
"      Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/46\">",
"      Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/47\">",
"      Valteau D, Hartmann O, Benhamou E, et al. Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/48\">",
"      Chao NJ, Kastrissios H, Long GD, et al. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 1995; 75:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/49\">",
"      Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/50\">",
"      Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997; 89:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/51\">",
"      Liu HW, Seftel MD, Rubinger M, et al. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2010; 78:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/52\">",
"      Litzow MR, P&eacute;rez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/53\">",
"      Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85:3334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/54\">",
"      Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/55\">",
"      Long GD, Negrin RS, Hoyle CF, et al. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 1995; 76:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/56\">",
"      Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/57\">",
"      Crown J, Kritz A, Vahdat L, et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/58\">",
"      Ayash LJ, Elias A, Schwartz G, et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/59\">",
"      Zujewski J, Nelson A, Abrams J. Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 1998; 90:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/60\">",
"      Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/61\">",
"      Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/62\">",
"      Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/63\">",
"      Schulz AS, Glatting G, Hoenig M, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011; 117:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/64\">",
"      Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults &gt; or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/65\">",
"      Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/66\">",
"      Gopal AK, Guthrie KA, Rajendran J, et al. Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/67\">",
"      Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/68\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/69\">",
"      Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/70\">",
"      Craddock C. Nonmyeloablative stem cell transplants. Curr Opin Hematol 1999; 6:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/71\">",
"      Little MT, Storb R. The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000; 105:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/72\">",
"      Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/73\">",
"      Carvallo C, Geller N, Kurlander R, et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004; 103:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/74\">",
"      Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/75\">",
"      Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/76\">",
"      Saito T, Kanda Y, Kami M, et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/77\">",
"      Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/78\">",
"      Belkac&eacute;mi Y, Labopin M, Hennequin C, et al. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 2007; 67:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/79\">",
"      Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/80\">",
"      Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/81\">",
"      Corradini P, Zallio F, Mariotti J, et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 2005; 23:6690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/82\">",
"      Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/83\">",
"      Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/84\">",
"      McClune BL, Weisdorf DJ. Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol 2010; 17:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/85\">",
"      Hermann S, Klein SA, Jacobi V, et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2001; 113:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/86\">",
"      Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/87\">",
"      MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000; 110:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/88\">",
"      Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110:2744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/89\">",
"      Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22:3886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/90\">",
"      Ueno NT, Cheng YC, Rond&oacute;n G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102:3829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/91\">",
"      Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009; 113:4458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/92\">",
"      Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/93\">",
"      Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/94\">",
"      Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/95\">",
"      Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/96\">",
"      Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/97\">",
"      Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/98\">",
"      Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/99\">",
"      Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/100\">",
"      Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/101\">",
"      Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/102\">",
"      Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol 2006; 132:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/103\">",
"      Sala-Torra O, Martin PJ, Storer B, et al. Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 2008; 41:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/104\">",
"      Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/105\">",
"      W&auml;sch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol 2000; 109:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/106\">",
"      de Weger RA, Tilanus MG, Scheidel KC, et al. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000; 110:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/107\">",
"      Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/108\">",
"      Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/109\">",
"      Michallet AS, F&uuml;rst S, Le QH, et al. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens. Br J Haematol 2005; 128:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/110\">",
"      Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/111\">",
"      Teshima T, Matsuo K, Matsue K, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 2005; 130:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/112\">",
"      Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/113\">",
"      Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008; 42:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/114\">",
"      Ciurea SO, Saliba R, Rondon G, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 2010; 45:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/115\">",
"      Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009; 374:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/116\">",
"      Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 2010; 115:5147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/34/25130/abstract/117\">",
"      Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010; 116:3080.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3557 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25130=[""].join("\n");
var outline_f24_34_25130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H103575063\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREPARATIVE REGIMEN INTENSITY DEFINED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMMON TOXICITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Total body irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MYELOABLATIVE PREPARATIVE REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiation-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chemotherapy without radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comparison of radiation with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MULTIPLE CYCLES OF HIGH DOSE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RADIOLABELED MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anti-CD45 antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H944694131\">",
"      Anti-CD66 antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anti-CD20 antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONMYELOABLATIVE AND REDUCED INTENSITY PREPARATIVE REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General principles and examples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antibody-based minimal intensity conditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103575063\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/23/13694\" title=\"figure 1\">",
"      Graft versus leukemia in CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/63/6139\" title=\"table 1\">",
"      Toxicity preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/2/10284\" title=\"table 2\">",
"      Radiation preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/26/26029\" title=\"table 3\">",
"      Chemotherapy preparative regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=related_link\">",
"      Chemotherapy-induced alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=related_link\">",
"      Hematopoietic cell transplantation in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=related_link\">",
"      Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_34_25131="Aeroallergen SCIT - One day - modified - B";
var content_f24_34_25131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified one-day schedule for aeroallergen SCIT - B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time (min)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dilution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Color vial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        Green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        0.15",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Protocol courtesy of Dr. Jay Portnoy.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25131=[""].join("\n");
var outline_f24_34_25131=null;
var title_f24_34_25132="Types of occupational rhinitis";
var content_f24_34_25132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Categories of occupational rhinitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Annoyance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Detergents",
"       </td>",
"       <td>",
"        Supermarket",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perfumes",
"       </td>",
"       <td>",
"        Department store",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Irritant-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Air pollutants",
"       </td>",
"       <td>",
"        Outdoor, inner city worker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoke",
"       </td>",
"       <td>",
"        Any workplace",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold air",
"       </td>",
"       <td>",
"        Meat packer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hairspray",
"       </td>",
"       <td>",
"        Department store",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Talc",
"       </td>",
"       <td>",
"        Cosmetics industry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Allergic/immunologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Natural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Guar gum",
"       </td>",
"       <td class=\"sublist_other\">",
"        Carpet worker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Latex",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nurse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psyllium",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nursing home",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rats",
"       </td>",
"       <td class=\"sublist_other\">",
"        Laboratory researcher",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Synthetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acid anhydride",
"       </td>",
"       <td class=\"sublist_other\">",
"        Epoxy worker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Platinum",
"       </td>",
"       <td class=\"sublist_other\">",
"        Jeweler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Toluene diisocyanate",
"       </td>",
"       <td class=\"sublist_other\">",
"        Spray painter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Corrosive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Ammonia",
"       </td>",
"       <td>",
"        Chemical plant",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25132=[""].join("\n");
var outline_f24_34_25132=null;
var title_f24_34_25133="Weight loss and fall in BP";
var content_f24_34_25133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Weight loss-induced reduction in diastolic blood pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 219px; background-image: url(data:image/gif;base64,R0lGODlh0QHbAMQAAP///wAzmYCAgAAZTAAAAEBAQMDAwBAQENDQ0CAgIODg4HBwcPDw8KCgoDAwMLCwsFBQUJCQkGBgYAAMJgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADRAdsAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGDCAYkDwIRCpKbnIwKDQcEIwsEDgcHmp2qq4ECBK8iDAQHABEEC6y5unuwAAYEBb7Au8TFcr2/wckiBgLOz5XG0tNevQilAA8EEMzPzgUC1OLjVAq/BAaaCQQPEAQNKM7k8/RLrq8E4QgOs7jx4fUCCqTRwJsABDvkDVzIcEUBfPii4VDYsKJFAAUiGDBQYEECbjkoXhwpkJ0IAeCC/4UESLIlvQQHBCw4AAGlDpEumhncybOnT4MSXQol8yDULAQLItxk+ULAhAFQo0qdSrWq1agTmA7dCobBRh84WwgYEKCs2bNo06pda3aAVq5wsej0Bi/hWxZj2erdy9Zt3L9Z7kFUuVRGXr6IEfsFzJiKzgQJnNUtHONw4strFzfeLKUAYR5h8ZLFTBqtZs6om3jmoROc4dGlY59OTbuIYHyfa7S+u8JybNKzawsHcvtV7huhe8P+jTn48OdfkqvwzTyxc+jYtUhPQb063+vZw8+IYHSY3dfem/MWz/7FLM8dQa/nvjz9XvDt86uITHx+vPr29eWffgSSYEBkksmHXv+A3w1YYIH84KZgZQAymBZ+Dz64zUYGIHQehRbe52CG+S0gQQwMFBQBA9ONSEJ3IZ6FIYn6PSThCgzw89ABLP6zYIxqzUhjewvAF98KvziAETrcuTgCjEAGIOSQVJqQYykJnNjkj1HK6GSVzzEQwTOTpcCABAes40CPvhjkGohdmvYlmMKtc6MKtoTjDktzfTMnlEBOSedzG27koQoNlGIAP2WWsN1/cco5aIYmxjATAfxtCWekZQk6aW2J3rkSl5F6+mlq73nmD2UwABqjqadylilYf1YYJayxNuYRmRO2amugc+bKmI3G9drUr68GK+xflHB46KibcorrsoM+eoL/qyFOSy2Y1pqArYXabktlt44im62y4o5bK6dtoZvuVgg0wCa0vrLbqbvvCvVLTPPOsBupcYabr74o4ftvtKXim9NPDDfcU1ADc0Lui+aCq7BYT12l8cZWZRUxHaTE9MPET1bMoMAufHvyxR9noU1EtALcJcpimRwgzS1jIUACDDAw64f12ouzcvZKyXLOVgjgwEYOSNChsSnbbN/Q00mdHtVIT1GceaweWzTWkAp9dNZTNGCkqlDX/PXY9K1NdiQkn2S1d2BfO3d1db/thAIIFdxD3ACofDPbYbObt95LKPCKO68o1UKK2wEu+NSE2+024mm48lABix53AgKhFJBA/4sy31q5t3czdzjmSNjkmk0srPOsjwgHfHq5l7NuhgAHFJCm6J6XcA1k25Be+8y3U5y77mRsHbyBijI6Qp9+H2+6ban/tjrzRJjDoaEsXBOMK3y6ua7Y2C/PvR3rPMAPxC+eb3jyJau/Ph37zNKoo/JLS7/c9rtfK/qXsPShT4BjMAcAvNIv5BDQdgacHwLH4ABu+ExLXYtaAMGSPdn8b4I+YFLgnjcDyXWwNNsD4AFB+IUDOA4CIMmg2lYohMld7YMs3IEESiE9oHmNhkGwId1wmMMcnKkff3sg8iLovyICwoQb/NsJgUNEJ9JAAJ+gS9pEE0XQTFE9RaCew8boE//4vQsdxOIavX4oQSIIEW8fdArH5khHj7XMAAxoFvh8qEEgEueLl0lh4ABpnSoODIp+HBkhFRPHRTYoZxARlW78VDpgMbGAbnSkiHJ2NrTh4GBBa+MQ3qi6RnbRivGrZLIuCcFMnnJbDHDHAVYlQy4mkoOvDIkm9SLI8GyOH2NDpChruEsBsXKJSDMJAIq0RaLdUoq5nEgxM2PI54gsljFcYx+HGcRpBsmUz0wXKfDxgGZWLZrI8eaFwMnNj0WgABAopznbFs6EqFNSrqynDsRIxn56w4y5aEA0HiDPWjqznYpEpw1Iqb04ZoyOEO1YNe3wJmbycYYIxaU+danQGjD/1IPGOAdEsrkCSqSCdqFsYj4zCs2NSrOjjUCA7xLgGQjMLgWgy4fxUorJUd7TS8e83kpVagyByiBC8xEmUYkJ0xL+tF1BtaQ0FnCQNDXwWrPUqaZ42kqfNlWV54rqKqVxgAZA4BS0RME1LqHVbnjjTVxFplddms6vWk+qxkDHR2A3nUiW761KFOpcWepFu8ZVsMX4SD4sqgLv7VACJ/VWYPHKVLou9Kn3EmtYpWELVCQgrX1N6mTHOtildtOwbDQtMRCgAAbOs3CqTahlPYpZo2nWYtMQE68uakvC2hO124ytRn3bCcYVi7cHFW5LicvR2V6xtr3Uwy3QGMzRbra0/z2tLHNf6lxHoAMVfNUmRpVb2O6CFbdDzS4xygoBmJDQMNZFL3a7ql3y/ta8MeCnP/cL0CM0oAGgO8BNFxrfld3WwOml72nx26qHRvTBUrHjG5Sq3j8Cd7wVlu1263phGhQAKUYCLYHPi+D5yrW+GR6ufW9SW9syAY2Dea3lGJzaFC93xc3d8GWL5uIJF3hwBwZygk+8YB3TlsfRlaxB9ucvSt6VtChWsIVpHFwbl5fKNYjkcW8AyhpLWcM45q6Rn9vh5Ib5BxtJgEY4Ul0SC9nEiC3ymXeM5d6OuQfKDO9Efky5IPd5yHGe8p3d/GYmwEQmNJEx6sp8zjqb+csqtv/yfR1Ng5weRdG4ozQ9B/3k60aZyILmNGv661E+39DPpwY0ZeUsaRYjeaJGoDCkb9zqHM/5yJqG7a3BIGtQg7nWYt61Uxm9aVFvodeB/vWsryxsQqcazslWA7JXHWpgc9jYVV72pLF9A1BIEgUKGNOKduplX0da267O9Yy5bedm7yB0nnQIPpS01XJHm9botrW16czuR+dbCLOMwQN6to7+ThvKrP73td19WGorW+FAqNQM1hFZ/jl7iKjGuKoRXm2I41rdMEjje0lgC1pSD672dvi5zY1vljN73x/vNw2KBB8Rn4AUGHTrM1CebZdvG+ZkBnmmZV5shjPBHQgyuKn/NQ5tjj/83i/3eNCFzoIP0zzeKvBrvXsO9Z9LfdhUr1/YVTj2FMD42yPutHw/3fV0E13XX784091wcE8n3OduNzrXVd5yvJeh7mu/e9v1HXe1l5jtg2/e0uGYccZv3O4d93uw9R6YxZey8Zd/fOAjn/iFU15nlm8o5kWv+cMLnu9RLzwOOnkkgzb67ev+vL87z2/Zvx72LtCyGvcs98w3HfJPR73XJe95oEcn9CAtfaFP7/SV0z7mtq/MTphc6t6T/vebD37z+y78vEcfBrofeauQj0J2fj/2xrd+8rGffSN8z1k56PLet5/650/9/Isu+0fX3wQ9DlgG8odhqpdy//Q3fPYHdrg3dAnoAuO0ZeLVbgM4f8DnfN1HeMRXe/j3Ar2TD5+Facqjf9BlfulneMvHeQfIA+hAAAwgACTlQOpXfqPHf8w3gdxXgN43gjrADvDkAOLXFORHRTEIg8r3Z+xXgtpng0NAVS9DfVf0g2A0hM+GeEg4eREogFWYAwjwf9VHgkQohTRYfxVIhRcIfTiIHKKwADbnglwYhTPYfjX4hQYYhsV3hSUkCqsRM2s4d21oeiY4hXN4gnmoh61jhz0ofS8IhFAoiEfohmDohxhYhgsFDKeAdbwXiL7nhYwYh45IhmN4fxmIF1omfpAjL+QmgZl4g52IgJ8odgvIiv+t2Fjv9zQsoCPYsHVWCIgNt4meSIe3B4m3iItLoA3c4A4FJVmH+IRF2IV7aIQUqIuquIpgoVPkY4sQmIrHGEgiyItFp41wx42jJI1tdXLg4E8F4GAQ9mATMI77RY7meI4QlY7ruF/l6I7nCI/x2E/zSI/oqI736DD5qI8RZY/9RGpEUHLLRACO0yZvxY/92JAO6SYM+ZAS2Y+eMZEW2ZAVeZEaKY8RuZEe+RM8lwSKkwAHQgAVl0ptADhcoJLHBms15JIv+QQNsA4JwISBA5P9QXc4OTI7iYcp2ZNiAZQeeHw6WZRGuZJCiVy7k5Su93dM2ZRUwJLa8ZSVyAZSWXn/PuYFX9EGW8kGXbkGX6kGYSmWBIlKZnmWaJmWaikICIAJJ6lHeOR+cUkC3rMRJzkD4XYQJlCX6fADeTluOmBSJeAV8IcEXnGXM9CWAmCTXEAJqzCXKZAoMIEKJZBGZZkDoQIxt6EVuxc+p9A+jgIRlUMs9PYkIgQDOaUVItWZO6AAqrknJvAQMgARaZgEkGkCBlAmnxAKq+A7C4CYABAKKUIAObcka3ZVPaAARqGZxGmXJCCZWFQL8FSMJkCMIxmaTtOXPjBwPnOaCvAQEgAPCCABHYGcI4BUJZAke4RmokAC+KCa6yAAldAOGbEC4tkLUOCbdxlegsEKZgMM1CkC/6/gFbv3EDzImDoAH6d5EpgCDvMSMlZ3C8SYAg9RTvjJoDQlAOaZAxQ3AgigJr95AA7AO6WJVaSgmu8BWUHwC97SViLgbQXQAMJICrUpAtcpBf9ZANSpZwBwoaogU8VDLACwQwmgIyVAVZcSoBMREeTxnQsKAA1AVeuQVuYhogtUPKb5Crn5Hj4apTtzCyEBMyJgkC/CJLZQTqRwKCJ1EOwwjSQwnihRiz2QRm3lpiQgmwDgDixiCmWqpSMwoVQApCChZRLho5xgAO7gAOWkRwtUEHYamoRTlwxAp2a0DO6pEuahRpKaDYvJmsJQiLC4ET2Ccy1aCa5gqqdJmOlQHP+8YahYaAC24JwM+hZ4WqvtaaMcwiKT+g5VgKilIE8bIQFLA5muCgkz2ZwosBGgQJmnCgCfdSmXaQPNwg/jNgwQIAFfypkkqQDE6AoJuZcExQ/l9At6gq3x+QNI5wxBQT4dsiEwkQKORZyaIJssGKegml+3ygyPBTEVigB5IozwqiPOAJxIcKxO4y2fYQ5aSrCLgK0beg82xaCVwDg1eQQPEQ3DwDtIFJoEgACxtLHJ+gqKygzSGAoB9wNaNwIKsA7ccKwOoIWmCRCy+QB2AgEbegMyVQKRVAJFgZDLFAo2mwKr+aRM4LAoEKV9+gpUuZZM27RO+7RQG7VSO7VUW7X/Vnu1WJu1Wru1VnuYahWtwgO2OOC1XKsKD/AmBaAlEFAAJ0muKICnKiuf8nYEblu2nTA8wqCCikMLzGBGriUCspmFJHsXlMAigXso3tMv2rlAt+kL/VW3BsKwdjsI68AASZooJ/KhryBgbmtpw2Cgr4ALEPGmdtKxoAumq2mhMPEKi1oewaC5l4ab+ZAjAnYl+DC5DcsOTTNLpAAPDsAz1+A0OiU7PRoMDyGjvGkLBzsCD4EQEQCkyCsK5vAJw4ApD2ALwUC8w/C7eUScJ0CuO1QJO6QUcIu7h4C57wABDsAPmhBJnKNTmWq87SmbkCugn2GrAKC5m1O89su//Ou+899bCuaBv+aLCLLwCtRbi5DRIwobDmnSv/hbv87KM/nrpIBrhyr4v5gaDA/Mvwtso7XwrclQoXlqkktSwInAD0qiOGAKpe9BU25LCr/7ufMrvbNQopJ5sfgrw+sQDPF7kDMcDInSOzQlCyaXD8qJCtpQpMWKwoBwCfI0JogrbgrgmtFQEABbEC8KEM3wrQCQl/CgxVAKEGPSDPCwmCdRF1iMpX+pANoQWVbMqeO6mHzqxLqgNL6jTEmAx6GgpBKnAgciOi1sx6zgmm7JBIacCWp1sws0JnpJyJAcyZI8yZRcyZZ8yZicyZq8yZzcyZ78yWkZAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between the quantity of weight lost and the fall in diastolic blood pressure in 308 moderately obese patients given a weight reduction regimen for 18 months. The patients began with a diastolic pressure between 80 and 89 mmHg; those who lost the most weight had the largest reduction in diastolic pressure. The decreases in the systolic pressure were similar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153:849.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25133=[""].join("\n");
var outline_f24_34_25133=null;
var title_f24_34_25134="Simvastatin major cardiac event";
var content_f24_34_25134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reduction in cholesterol with simvastatin reduces major coronary events",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Based upon a 5.4 year follow-up from the 4S trial, there is a direct relationship between major coronary event (MCE) risk reduction at one year and the percent reduction (right panel) and the absolute reduction in serum LDL-cholesterol (right panel). The red lines indicate the 95 percent confidence intervals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pedersen, TR, Olsson, AG, Faeryeman, O, et al, for the Scandinavian Simvastatin Survival Study Group, Circulation 1998; 97:1453.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25134=[""].join("\n");
var outline_f24_34_25134=null;
var title_f24_34_25135="Migration of abdominal aortic endograft";
var content_f24_34_25135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Migration of abdominal aortic endograft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast angiogram demonstrates downward migration of endograft into the aneurysm sac (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_34_25135=[""].join("\n");
var outline_f24_34_25135=null;
